Advocate Aurora Health

Advocate Aurora Health Institutional Repository
Aurora Health Care Books, Documents, and
Pamphlets

Aurora Health Care

November 2018

Aurora Health Care Metro Region Cancer Program Annual Report
2000
Aurora Health Care

Follow this and additional works at: https://institutionalrepository.aah.org/ahc_books
This Pamphlet is brought to you for free and open access by the Aurora Health Care at Advocate Aurora Health
Institutional Repository. It has been accepted for inclusion in Aurora Health Care Books, Documents, and
Pamphlets by an authorized administrator of Advocate Aurora Health Institutional Repository. For more
information, please contact AAH-Library@aah.org.

VuuL.J1

x

LflQ
r-IrW

! (‘c’.i r ) ri

r1ccNQ

CANCER

SERVICES

REPORT

onients
METRO REGION CANCER SERVICE REPORTS

2

William Laffey, MBA Regional Director of Cancer Services

3

Jeffrey Derus, MD

4

-

-

St. Luke’s Medical Center

William Donegan, MD

-

Sinai Samaritan l\’Iedical Center

Rakesh Jagetia, MD West Allis Memorial Hospital

6
8

-

Jonathan Treisman, MD Hartford Memorial Hospital

10

Lisa Robinson, RHIA, CTR Regional Clinical Data Registries

12

IN DEPTH REPORTS

14

-

-

-

SPECIAL FOCUS ON PROSTATE CANCER

Screening Detection and Prevention Mark Waples, MD

15

Surgical Management Jeffrey Derus, MD

20

Prostate Seed Implants Mitchell Pincus, MD

24

Prostate Seed Implants Behind the Scenes

27

-

-

-

-

Steve Belanger, BS, CMD

Treatment of Incontinence and Sexual Dysfunction

-

Stuart Fine, MD

29

Current Aspects of Hormonal Treatment Brian Butler, MD, FACS

32

Chemotherapy for Prostate Cancer Ronald Hart, MD

36

Pathology of Prostate Cancer Jorge Pellegrini, MD

39

Recent Advances in Prostate Cancer Genetics Angela Mengelt, MS

44

Oncology Program for End of Life Care Mary Runge, MSN

48

Metro Region Research Studies for Prostate Cancer

50

CANCER CONFERENCES IN THE METRO REGION

54

REGIONAL ACTIVITIES IN AURORA’S METRO REGION

56

Community Outreach and Events

57

Vince Lombardi Cancer Counseling Services

58

Support Groups

60

1999 Site Table and Statistical Review

62

-

-

-

-

-

I’

•1

Nc

CANCER

SERVICE S

REPORT

re.gtQn ai........c....1.r.e...c.,t.,o.r
Cancer Services

Prostate cancer is the second leading cause of cancer death in men.
The five-year survival rate for prostate cancers discovered in the early

Regional Director,

stages is 100%. If these statements seem conflicting to you, you’re not
alone. The challenge of education and early detection is one of the

William J. Laffey, MBA

reasons for the focus of this year’s Metro Region annual report. Many
symptoms of prostate cancer may be similar to those caused by benign
conditions such as infection or prostate enlargement. A number of
men feel that testing for prostate cancer is difficult or uncomfortable,
and would rather go untested.
The inherent danger in this ‘benign neglect’ is that 700 Wisconsin
men are expected to die this year from prostate cancer, comparable to
the number of deaths expected from breast cancer. While our annual
report is often geared toward health professionals, we truly hope that
by focusing on this disease site we will continue to spread the message
of testing and early detection espoused by Senator Bob Dole at our
first annual Men’s Health Conference.
Within this report, physicians and Aurora Health Care staff discuss
prostate cancer from the viewpoint of detection, screening, medical
and surgical treatments, seed implants, pathology, genetic factors and
others. We share with you our care, compassion, intellect, technological
advances and cutting-edge research. We have treated more cancer
patients than ever and continue to enhance our reputation as an
outstanding cancer program.
Most importantly, we hope that this annual report will cause additional
men to seek early detection of prostate cancer. In that way, the
partnership between patient and provider will allow us to maximize
our success in cancer treatment.
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LUKE’S

St. Luke’s Medical Center

MEDICAL

CENTER

Looking back on the activities of the cancer committee during
the past year, several exciting developments have occurred.

Jeffrey A. Derus, MD

On September 26, 2000 we had our first Men’s Health Fair
at the Italian Community Center. The focus of the health fair

was prostate cancer with Senator Bob Dole giving the keynote
speech, “Life After Prostate Cancer”. It was a wonderful
presentation and over 500 people attended. Other health
issues covered at the health fair were hypertension, stroke
prevention, glaucoma and coronary arterial disease. Numerous
physicians were on hand to answer questions. I would like
to thank them for volunteering their time. I would like to

give

a special thanks to Bob Reitman, Gary Grunau and Ken Sanders
for sponsoring the golf outing the previous day and raising
money to support the Men’s Health Fair and prostate cancer
awareness. The health fair was such a success that plans are
already in the works for the second annual Men’s Health Fair
next year.
Last year St. Luke’s Medical Center was notified that it received
accreditation for its cancer services for a three year period from
the American College of Surgeons. In 1999 Marija Weidman
was recruited and hired as a new business and market
development representative for the cancer services in the
metro region. She previously served in other management
roles within Aurora and began her new job in January 2000.
She is a tremendous asset to the cancer program at St. Luke’s
and throughout the region.

Several Vince Lombardi Cancer Clinics (VLCC)

St. Luke’s Medical Center, and now Hartford

have opened this past year, with the help of

Memorial Hospital. The Regional Cancer

Patty Abella, Regional iVlanager. West Bend

Committee has continued to work toward

opened their doors in April 2000. Melody Wilson
was the guest speaker for the grand opening

integrating the cancer programs throughout

and over 800 people attended. Another new
facility opened in Lakeland in November 1999.
We are also looking forward to expanding to
Oshkosh, Fond Du Lac, Green Bay, Burlington,
and western Waukesha in the future. I would
like to congratulate Kerr)’ Twite, RN, CNS
on her promotion to regional clinical nurse
specialist for all Vince Lombardi clinics and
radiation oncology.

the Aurora metro area.
In the fall of 1999, St. Luke’s opened the first
operational Gamma Knife in Wisconsin. The
Gamma Knife is a state-of-the-art highly
technological tool dedicated to performing brain
tumor surger The Gamma Knife radiosurgery
precludes the need for open brain surgery or
hospitalization. The patients are treated as
outpatients. A new CT simulator is now being
employed to allow more precise treatment

The community outreach activities that have

planning in radiation oncology. St. Luke’s Medical

taken place throughout the year can be found

Center will be the first institution in the city to

in the Education Outreach Activities in the

have the new CT simulator and will also be a

annual report. The Vince Lombardi Golf Classic

demonstration site for GE.

and Ball was, again, a great success. Special
thanks for the generosity of the volunteers and

It was an honor and pleasure to chair the

the support from the Vince Lombardi Cancer
Clinic. The Breast Cancer Race For Cure
took place on October 24, 1999. There were

cancer committee at St. Luke’s. I would like
to personally thank the members for their hard
work and dedication.

approximately 2900 participants who raised
over $1 50,000. Of that money, 25% went to
the National Susan G. Komen Foundation for
research and 75% went for grant requests
in the metropolitan Milwaukee area.
In 2000 we continued our quarterly meetings
of the regional cancer committee which consists
of representatives from ‘West Allis Memorial
Hospital, Sinai Samaritan Medical Center,

I

SINAI

SAMARITAN

MEDICAL

CENTER

s.r.e.p.ort.s.
.chairoer.s.on
I
Sinai Samaritan
Medical Center
William L. Donegan, MD

During the past year a number of initiatives have been taken
at Sinai Samaritan Medical Center to improve care for cancer
patients. A working group was established to implement
a tracking system in clinics to remind physicians when their
patients are due for routine mammograms and pap smears.
In a formative stage is a quality improvement plan that will
use the PDSA model (plan, do, study, act) as a framework to
improve oncology services. Oza Holmes, RN was on the planning
committee for the Susan G. Komen Race for the Cure that was
held for the first time in Milwaukee on October 24, 1999 and
which was a large success. Seventy-five percent of the funds
raised through this event support education and services for
breast cancer patients in the greater Milwaukee community.
The nationwide breast cancer prevention trial known as STAR
began in July 1999. Sinai Samaritan Medical Center is one of
more than 400 recruitment centers across the country Julie
Jensen, RN serves as the coordinator for institutions in l’vlilwaukee
and as far north as Green Bay. The research activity at Sinai
Samaritan Medical Center is now documented and published in a
brochure that lists all active protocols at Aurora hospitals, a project
of the committee of research nurses. This ready reference helps
physicians make patients aware of additional options for treatment.
A modern treatment method that became available to our patients
during the year was the Gamma Knife installed at St. Luke’s
Medical Center. This equipment permits more effective radiation
therapy for brain cancers. Many thanks to Phil Whitton, Regional
Manager of radiation oncology for coordinating this effort.
Sinai Samaritan Medical Center contributed to the patient care
evaluation study of early stage breast cancers of the American
College of Surgeons.
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Results at Sinai Samaritan Medical Center

Barbara Haag-Heitman worked with the site

will be compared with those from institutions

implementation group at Sinai Samaritan Medical

across the nation. The creation of a Vince

Center to streamline screening and diagnostic

Lombardi Cancer Clinic at Sinai Samaritan

services for breast cancer patients. Close

Medical Center was discussed, and we look

connections with sister hospitals is also anticipated

forward to this development.

through a combined cancer registry software system
being planned by Lisa Robinson, the Aurora

The Cancer Committee at Sinai Samaritan

Metro Region clinical data registries supervisor.

Medical Center has gradually taken on a broader
look since metro regionalization. A uniform

2000 was an eventful year, one that saw new

statement describing our cancer committees

things happening and progress being made.

has been prepared for the bylaws of each metro

It was a privilege for me to

institution. We enjoy our working relationship

talented and dedicated individuals who compose

with Mr. William Laffey, the Aurora cancer

the Cancer Committee at Sinai Samaritan

services director, and during this year welcomed

Pvledical Center. On behalf of the Cancer

the return of Marija Weidman in her new

Committee, I wish to thank all who contribute to

capacity as the cancer services manager for

the high quality of cancer care at our institution.

work

with the

Business and Market Development and the
services of Kristin Niendorf and Angela Mengelt,
the Aurora genetic counselors.
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WEST

ALLIS

MEMoRIAL

HOSPITAL

.chairper s...c....ns.. reports
West Allis
Memorial Hospital
Rakesh Jagetia, MD

A significant number of changes have taken place at West Allis
Memorial Hospital over the past year. Most noticeable are
the physical changes, with a new Women’s Pavilion under
construction and a new Radiation Oncology suite in the planning
stages. A comprehensive prostate cancer program has been
expanded, now having the availability of both prostate seed
implantation and cr oablation. Our commitment to excellence
in cancer treatment, however, is exemplified not only with
building projects and technology, but also in the dedicated
and talented professional staffs who provide care, education
and treatment. As newly elected Chairman of the Cancer
Committee, I am pleased to be able to work more closely
with these individuals as we try to meet the challenge of
providing high quality cancer care at West Allis Memorial
Hospital. I would like to extend the appreciation of the Cancer
Committee and the entire organization to Dr. Maury Berger,
who chaired the committee for many years before making the

decision to relocate his practice outside the l\’Iidwest. His
dedication to the cancer program will be remembered.
Committee members Dr. Terry Roth and Dr. Craig Evans were
instrumental in the metro region’s establishment of a committee
to explore membership in the American College of Surgeons
Oncology Group (ACOSOG). This organization is dedicated
to performing prospective, randomized trials evaluating
surgical therapies in the management of patients with solid
tumor malignancies.

-4

As a result of this leadership, over twenty Aurora

Finally, we were pleased to organize patient

physicians have been accepted for membership

care evaluation studies around the topics of

and awarded the right to participate in the

brain tumor and hepatocellular carcinoma, and

American College of Surgeons Oncology Group

participate in the Public Broadcasting System’s

national trials for their patients.

series on End of Life issues. The educational
aspects of cancer care, whether in weekly

Committee members were also most active

cancer conferences or annual seminars, are

in the educational component of cancer care.
Many members attended presentations given by
the Washington, DC based Oncology Roundtable
on “Redefining the Patient Experience in Breast
Cancer Care”. Other members participated

most important to our Cancer Committee
members. Through these efforts, we afford
our patients access to the latest treatments in
cancer care and the combined energy of health
professionals with varied fields of expertise.

in the Southeastern Wisconsin Cancer
Conference on malignant melanoma, and still
others volunteered their time at Aurora’s first
Annual Men’s Health Conference, answering
questions for the 500 attendees in a private,
consultation-like setting.
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HARTFORD

Hartford Memorial Hospital

MEMORIAL

HOSPITAL

Washington County has seen explosive growth, and
Hartford Memorial Hospital has been responding with

Jonathan Treisman, MD

enhancement of services. This includes consolidation
of cancer services and the initiation of a formalized
cancer program. This new program will enhance
the quality of patient care through prevention, early
diagnosis, pretreatment evaluation, staging, treatment,
rehabilitation, surveillance for recurrent disease,
psychosocial support and the hospice concept.
The Cancer Committee offers the opportunity for
multidisciplinary collaboration on projects that
strive to improve cancer care at the institution.
One collaboration has been between hartford
Memorial Hospital and St. Joseph’s Hospital in
West Bend. Patients are now being offered Radiation
Oncology services at St. Joseph’s and outpatient
chemotherapy services at both the new West Bend
Vince Lombardi Cancer Clinic as well as the Vince
Lombardi Cancer Clinic in Slinger. The medical!
surgical unit at Hartford Memorial Hospital was also
named the Oncology Unit with Linda Martin as its
Director. The cancer registry data will be maintained
on a modern database platform.
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Tumor board is one of the best

ways

to integrate

The establishment of a Cancer Committee

disciplines of care for cancer patients. In a

at Hartford Memorial Hospital has been an

community setting, especially with commuter

exciting development. The next exciting step

physicians, attendance is a special challenge.

will be its integration into the i\’Ietro Regional

Although video conferencing has been

Cancer Program.

proposed, the Hartford Memorial Hospital
Cancer Committee has proposed exploring
the development of an on-line tumor board,
in which physicians and other health
professionals can log-on and provide input.
The Hartford community has shown its
emotional involvement in the pursuit of
cancer treatment in its wonderful turnout
for the Relay for Life, an annual event at
Hartford High School.
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In October, 2000, the Cancer Registrars of the Metro Region joined
their peers at the 25th Anniversary Meeting of the ‘Wisconsin Cancer

Lisa Robinson, RHIA, CTR

Registrar’s Association. The keynote speaker for the

event

was

April Fritz, RHIA, CTR, a former Milwaukee registrar who currently
works for the National Cancer Institute. Ms. Fritz noted the extensive
strides made in cancer over the last 25 years. It is hard to believe
that in the past, registrars were merely responsible for collecting
information on approximately 20 data elements for each cancer
patient accessioned into a hospital’s tumor registry!
Today the Aurora Metro Region’s ACOS approved cancer registries
date back 15 years and currently collect well over 1 70 data elements
per patient. More importantly is the fact that this data can be accessed
immediately through computerized software and can subsequently be
reported out in a variety of combinations and formats. l’vletro Region
physicians, administrators and key personnel may request information
from this rich database for purposes of assessing patient outcome,
facilitating research, assisting with marketing, administrative planning,
and quality benchmark purposes.
In 1999, the registries of Aurora Health Care’s Metro Region including
Hartford Memorial Hospital, St. Luke’s Medical Center (including the
main and South Shore campuses), Sinai Samaritan Medical Center,
and West Allis Memorial Hospital accessioned 3,001 new cancer
cases (See Site Table, page 62), satisfied over 30 requests for data,
participated in the American College of Surgeons (ACOS) patient
care evaluation (PCE) study on malignant melanoma, and voluntarily
submitted abstracts for a quality outcome study. In addition, the
registrars routinely coordinate and attend site-specific cancer case
conferences, participate in cancer committee meetings and complete
physician-assisted quality control studies on 10% of the analytic
case load.

In compliance with state statute and ACOS
requirements, new cancer cases are submitted
to the Wisconsin Cancer Reporting System and
year-end data is blinded and submitted to the
National Cancer Data Base. Types of information
that will be benchmarked for statistical analysis
include demographics, family history, diagnostic
work-up, tumor assessment, staging including
nodal, regional and distant disease status, treatment

Metro Region Clinical Data Registrars
Sharon Collison, RHIT
Christine Doege
Deborah Dries, RHIT
Judith Ferkans, RHIT
Cynthia Ganzel, RN, RHIT
$heri Hackbarth, RHIA

type, applicable recurrence and subsequent
treatment information, as well as yearly lifetime
follow-up. All information is kept strictly confidential

Jamie Keen

and only aggregate data is released. It is hoped
that beneficial conclusions can be drawn from

Ramona Miranda

this in-depth array of longitudinal data.

Mary Kissinger, RHIA, CTR
Tracy Miller
Karen Poflock
Marilyn Raciti, RuT, CPHQ

Dispersed within this year’s annual report you will
find 5 year data on prostate cancer pulled from
the standard data set of the three main campuses
(St. Luke’s Medical Center, Sinai Samaritan
]\‘Iedical Center and West Allis i\’Iemorial
Hospital). This standardized data is compared to

Lisa Robinson, RHM, CTR
Jane Seymour, RHIT, CTR
Lisa Stachowiak
Holly Stowe-Behling
Lisa l47hite

the national statistics of the National Cancer
Data Base (NCDB) from 1995. Also included
within this report, but without NCDB comparison,
is in-depth or ad hoc data compiled from 1998’s
ACOS PCE on Prostate Cancer; this information
was gathered strictly from our largest institution,
St. Luke’s l\’Iedical Center. Many thanks go out
to Marilyn Raciti, RuT, CPHQ for compiling the
prostate study statistics.
It is our hope that you benefit from the in-depth
site study reports on prostate cancer that follow.
For references on any of the enclosed reports or
if you would like to request information from any
or all of the Metro Region cancer registries,
please feel free to call (414) 649-7290.
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Prostate cancer is the most commonly diagnosed malignancy in
men and has the second highest rate of mortality behind lung

Mark J. Waples, MD, FACS

cancer. An incidence rate of 244,000 new cases with 44,000
deaths related to prostate cancer was estimated in 1995. There is
greater public awareness of prostate cancer related to an increasing
incidence, an aging population and media attention. The etiology
of prostate cancer is not particularly well defined. Risk factors
include family history, age and race. Prostate cancer is more com
mon and seems to be more aggressive in black men. Conversely,
Oriental men have a relatively low rate of prostate cancer that in
part may be explained by low dietary fat intake. A brief overview of
recent developments in prostate cancer screening and detection

will be presented.
Prostate-specific antigen (PSA) has revolutionized the management
of prostate cancer. PSA is utilized in early detection, staging and
monitoring of prostate cancer patients. The sensitivity of PSA>
4.0 ng/ml for detecting prostate cancer is approximately 80%.

However, specificity and positive predictive value for PSA is relatively
low with 60% to 80% of patients with PSA values between 4 and
10 proving not to have prostate cancer. A variety of PSA derivatives
have been proposed to improve the performance of the test
including age-specific PSA, PSA density and PSA velocity.
However, there are significant controversies with all of these
derivatives. Another approach has been the utilization of new
assays of various molecular forms of PSA. Free to total PSA ratio,
PSA complexed with alpha-I antichymotrypsin (cPSA), reverse
transcriptase-polymerase chain reaction PSA and a human
kallikrein PSA are examples of these new approaches. Further
refinement of the PSA derivatives and the new PSA assays will
continue to occur resulting in improved performance of this
important tumor marker.

15

Digital Rectal Examination (DRE) is the second
tool available for initial detection of prostate

A reasonable approach to early detection in an
individual patient is to have an informed consent

cancer. Approximately 20% of patients with
prostate cancer will have a normal PSA thus

discussion. Present the patient with the risks and
benefits of screening with PSA and digital rectal

making DRE mandatory in any early detection
or screening program. Conversely, the positive

examination and allow these men to decide
whether to undergo investigation. Patients with

predictive value of an abnormal DRE is only
approximately 20%. Prostatic stones and BPH

a family history of prostate cancer and African

nodules are palpable abnormalities that cannot
readily be distinguished from prostate cancer
without the use of ultrasound and/or biopsy.
Screening for prostate cancer is controversial.
Currently, there is no definite evidence that
screening for prostate cancer using PSA and
digital rectal examination decreases mortality
from prostate cancer. Some observers feel PSA
screening will go the way of routine chest x-ray
screening for lung cancer, whereas others are
convinced of the value of prostate cancer
screening. There are several natural occurring
‘experiments” in this country based on different
levels of PSA utilization in various geographic
areas. Specifically, patients in Utah and the
Pacific Northwest have utilized PSA screening
to a greater extent than those in Connecticut.
Therefore, a comparison of mortality rates from
prostate cancer in these regions over time may
provide additional insight into the value of
screening. Additional support for prostate cancer
screening comes from two recent European
studies which suggested PSA screening resulted
in detection of prostate cancer at an earlier stage
than historical controls.
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Americans are at high risk for prostate cancer and
should be offered early detection beginning at age
40, whereas other men should be offered early
detection at age 50. Both the American Cancer
Society and the American Urological Association
support this approach.
The histologic diagnosis of prostate cancer is
most commonly obtained by transrectal ultrasound
guided biopsy of the prostate. Other diagnostic
modalities consist of transurethral prostatectomy,
transperineal biopsy and as an “incidental” diagnosis
at radical cystoprostatectomy performed for bladder
cancer. Indications for transrectal ultrasound guided
biopsy include an elevated PSA or abnormal digital
rectal examination. Transrectal ultrasound guided
biopsy of the prostate is carried out under local
anesthesia with sampling of all ultrasound and digital
rectal examination abnormal areas. Additionally,
patients with an elevated PSA undergo systematic
sampling of the prostate. Historically, this has
involved 1 “sextant” biopsy of the prostate including
bilateral sampling of the base, mid-gland and
apex of the prostate. However, recent literature
has suggested the need for a greater number of
biopsies as well as sampling of the deeper zones
of the prostate with a variety of new biopsy arrays
being advocated.

Preparation for transrectal ultrasound guided
biopsy includes an enema and a fluoroquinolone
antibiotic. The pathologist plays a critical role
for patients with prostate cancer both in making
the diagnosis and assigning a Gleason grade to the
tumor. The Gleason grade along with PSA and
clinical stage provide a basis for predicting the
behavior of the cancer. Prostatic intra-epithelial

In summary, detection of prostate cancer involves
PSA, DRE and transrectal ultrasound guided biopsy
of the prostate. Screening for prostate cancer
remains controversial, but additional studies and
information are forthcoming. The decision to
utilize PSA and DRE should be individualized to
each patient.

neoplasia is a pre-malignant condition that when
present on needle biopsy necessitates careful
follow-up.

RACE I ETHNICITY
The American Cancer Society National Cancer Data Base 1 998 Prostate Cancer Report indicates that the proportion of African Americans
diagnosed with this disease has increased 34% from 1992-1995 (8.8% to 11.8%). This trend was most evident in all regions of the country
except the Midwest which showed little change (0.1%). Data for 1995 at St. Luke’s and West Allis Memorial shows a much smaller proportion
(2% and 3% respectively) of African Americans diagnosed at those sites while Sinai Samaritan diagnosed a number much greater than the
NCDB national and Midwest percentages (SSI’vIC 62%, NCDB national 11.8%, NCDB Midwest 8.2%). According to ACS Cancer Facts &
Figures 2000, black Americans have the highest prostate cancer incidence rates in the world.
It should be noted that on a national level there was a fairly substantial percentage (9%) of cases identified as other and unknown. It is also
interesting to note that the incidence of prostate cancer diagnosed in Asians at the Metro level was none and at the national level only 1%.
The percentage of l-lispanic patients at each of the Metro hospitals varied from 0% to 4.8%, but the average percent for the Metro Region
as a whole (2.1%) was just slightly lower than the national percentage rate of 4%.

Race

• Other and Unknown
• Asian
• American Indian
• African American
• White
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DIAGNOSTIC EVALUATIONS
St. Luke’s Medical Center

—

199$

early stage.
Various tests are used to diagnose and stage prostate cancer. PSA tests, along with DREs, are used to detect the cancer at an
further
for
needed
are
which
decide
tests
and
prognosis
If prostate cancer is confirmed by a biopsy, PSA results are used to help predict
diagnostic
additional
If
decisions.
indicated,
treatment
making
and
disease
the
of
evaluation. PSA tests are also used to assist in staging
chest x-rays,
tests may be recommended to determine the extent of spread of the disease. These may include lymph node dissections,
during
patients
cancer
on
prostate
Luke’s
St.
at
done
evaluations
diagnostic
the
of
some
of
table
A
MRIs.
and
scans
CT
scans,
bone
cancer.
showing
tests
1998 follows. findings are also displayed including percentage of abnormal

Diagnostic Evaluations
Total Tests
Peormed

Type of Tests

Abnormal
Cancer (and %)

Abnormal
Not Cancer

Bone Marrow Aspiration

2 (100.0%)

0

0

2

Normal

Bone Scan
Bone X-ray

14

(13.9%)

17

70

101

2

(15.4%)

3

8

13

Chest X-ray
CT of Abdomen

11

(70.6%)

8

85

104

8

7

39

54

CT of Pelvis

14

(74.8%)
(24.1%)

5

39

58

IVP

2

(40.0%)

0

3

5

MRI

2

(33.3%)

1

3

Pelvic LN Dissection

2

(10.5%)

1

16

6
19

142
8

(94.0%)

0
2

9

151

2

12

PSA
Ultrasound of Abdomen

(66.7%)

DIAGNOSIS UNDER AGE 65
prostate cancer under age
According to the 1998 NCDB Annual Review of Cancer Patient Care, the proportion of patients diagnosed with
with this type of
diagnosed
being
are
patients
that
indicates
change
important
This
1995.
in
29.8%
to
65 was 21.3% in 1992, increasing
a move in pattern
indicate
this
may
disease,
of
stage
earlier
an
cancer at a younger age. When combined with the shift toward diagnosis at
use of PSA
increased
of
result
a
be
may
diagnosis
Earlier
.
management
expectant
or
palliation
than
rather
of care to curative intervention
of
patients
28.6%
with
data
national
to
comparable
is
testing as a screening mechanism. 1995 data from West Allis Memorial Hospital
patients in that age group while
diagnosed before age 65. Sinai Samaritan Medical Center diagnosed a slightly lower percentage (23.8%) of
65 years.
than
younger
an
at
age
diagnosed
at St. Luke’s Medical Center, a greater number (38.1%) of its patients were

Diagnosis Under Age 65

Age less than 65
Age 65 and over

age

PRESENTING SYMPTOMS
St. Lukec Medical Center 199$
—

According to the National Cancer Institute, most men with prostate cancer have no symptoms as this type of cancer can grow quietly
for years.
When symptoms do occur, they are similar to those caused by other noncancerous disease. Common symptoms include difficulty urinating,
a weak
stream, a frequent urge to urinate especially at night, pain or burning on urination, and blood in the urine. As can be seen in the accompanyin
g
graph. only a small number of patients at St. Luke’s presented with symptoms, the most common of which was trouble urinating.

Presenting Symptoms
•Yes INo SUnk]

Cl)

0
U

13
Trouble Urinating

11

13

—,
hematuria

Lower E

SYMPTOMS

BIOPSIES PROCEDURE
St. Luke’s fvledical Center 199$
-

Procedure

—

If prostate cancer is suspected, either because of symptoms
or early detection screening, a biopsy is done to confirm that
the disease is present. The biopsy is usually performed in the
urologist’s office. The most common method is the needle
core biopsy. During the year 1998 at St. Luke’s, 67% of
patients having a biopsy had a needle core biopsy.

Type
Incisional
FNA
Needle Core
Sextant
Unknown
Not done

Number Performed
46
5
106
2
1
14

BIOPSIES GUIDANCE
St. Luke’s Medical Center 199$
-

Guidance

—

The urologist usually performs the prostate biopsy guided by
some type of technique, the most common being ultrasound
guidance. With this method, high frequency sound waves
create an image or picture on a video screen, assisting the
physician in obtaining the biopsy. Multiple tissue specimens
are normally taken from different areas of the prostate. Of
those patients at St. Luke’s for which data is known, 76%
had a biopsy using ultrasound guidance in 1998.

Type
Guided
Radiographic
Ultrasound
Not guided
Unknown

Number Performed
7
1
104
25
37

-

BIOPSIES -APPROACH
St. Luke’s Medical Center 199$

Approach

—

Most prostate cancers develop in the lower portion of the
prostate situated closest to the rectum. For this reason the
transrectal approach is the most commonly used to obtain
biopsies. In 1998 at St. Luke’s, 84% of patient cases with
approaches known had prostate biopsies done transrectall

Type
Transrectal
Transperineal
Transurethral
Unknown
No biopsy

Number Performed
98
6
13
45
12
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SURGICAL

TREATMENT

I
Chief of Urology
St. Luke’s Medical Center

Over the past decade, there have been a number of major advances
in the diagnosis and treatment of prostate cancer. Through the use
of digital rectal examination, prostate specific antigen (PSA) testing
and improved biopsy techniques, it is now possible to diagnose
prostate cancer in more men at an earlier, more curable stage.

Jeffrey Derus, MD
The prostate is one of the male sex glands. Other major sex glands in
men are the testicles and the seminal vesicles. Together, these glands
secrete fluids to make up the semen. The prostate is about the size
of a walnut. It lies just beneath the urinary bladder and surrounds the
upper part of the urethra. The urethra is a tube that carries urine
from the bladder and semen from the sex glands out through the
penis (See Diagram below).

Seminal Vesicle

4.

Urinary Bladder

Rectuih
Prostate
Urethra
Anus

Penis

Scrotum

Testicle

One can feel the prostate by doing a digital rectal exam. Prostate
cancer is suspected when the patient has either an abnormal digital
rectal examination or elevated PSA. This will ultimately lead to a
transrectal ultrasound and biopsy of the prostate to confirm if cancer
is indeed present.

V

The radical retropubic prostatectomy is the most commonly performed
surgery for localized prostate cancer, Stages Ti and T2. It involves
removal of the entire prostate gland, the seminal vesicles and
re-attaching the urethra to the bladder.
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The indications for surgical removal of the prostate
should be reserved for those men who have local
ized cancer, who are likely to be cured and who
will live long enough to benefit from the treatment.
The factors that influence the risk to benefit ratio
for surgery include the patient’s age and health,
the nature and stage of the cancer, the probability
of surgical cure of the cancer and the complications
of surgery.
The retropubic approach to radical retropubic
prostatectomy was pioneered by Millin in 1947.
Over the next decade, the technique was adopted
by others; however, it never gained widespread
popularity because of the significant complications
of bleeding, incontinence and impotence.
Over the past 20 years a series of anatomic
discoveries have improved the surgeon’s ability to
remove all of the prostate cancer and substantially
reduce the
morbidity, specifically
pen-operative

incontinence and impotence. The delineation of
the anatomy of the dorsal venous complex and
improved hemostasis allows precise anatomic
dissection in a bloodless field. The apex of the
prostate, urethra and external urinary sphincter are
readily identified, minimizing the risk of
urinary incontinence.
Over this period of time, another anatomic
discovery was made identifying the pelvic nerves
and neurovascular bundles in relationship to the
which are responsible for male erections.
Techniques have been modified to make it
possible to preserve sexual function. Before the
development of the anatomic approach to radical
retropubic prostatectomy with the identification of
the neurovascular bundles, virtually all patients
prostate

were impotent after surgery. It was not until 1982
that the exact location of the neurovascular bundles
in relationship to the prostate and the penis were
identified. In 1982, Dr. Walsh and Dr. Docker
described the anatomy of the pelvic floor,
neurovasculature and its importance for erectile
function. Since that time, the nerve sparing radical
retropubic prostatectomy has been modified and
perfected to help preserve erectile function.
Recently, a new device called the Cavermap, a
nerve stimulator, has been employed to help
identify the neurovascular bundles. This is a
nerve stimulator that is used intra-operatively
to identify the neurovascular bundles along the
posterior aspect of the prostate. We have been using
this device for the past 6 to 9 months at St. Luke’s
Medical Center with improved preservation of
erectile function.

one’s

Three

have been identified that correlate
sexual
They
patient’s age, clinical and pathologic stage and the
with

factors

the

surgical

return

of

technique

function.

(i.e.

preservation

are

or

the

excision

of

the neurovascular bundles). Patients who have the
best recovery of sexual function are those who are
young and have organ confined disease. These
the most benefit from the nerve
procedure.

patients

see

sparing

Trends for the future focus on less invasive
surgical procedures, laparoscopic radical
retropubic prostatectomy and possibly robotics
radical retropubic prostatectomy.
These techniques are currently being developed
and are not in widespread clinical use. Their
use may increase over the next three to five years.
to perform

a
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Reference 1
AGE CATEGORY DIAGNOSIS

Metro level and nationally were diagnosed with prostate cancer
As can be seen from the graph, the majority of patients at both the
next on a national level by only 1% difference, and at Sinai
between ages 60-69. Of interest is that the age category 70-79 ranks
r In contrast, St. Luke’s and West Allis show a percentage
Samaritan an equal number of patients were diagnosed in that age catego
2000, and as illustrated in the graph, the incidence
figures
&
drop of 16% and 9% respective]v in that age group. Per Cancer facts
.
cancer
other
any
of prostate cancer increases with age more rapidh’ than
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TREATMENT FOR LOCAL DISEASE
St. Luke’s Medical Center 1998
—

with prostate cancer had local disease. The two most
During 1998 at St. Luke’s Medical Center, 87% of patients diagnosed
are the radical retropubic prostatectomy and external
common curative modalities used in the treatment of early stage cancer
local disease in 1998 were treated by radical prostatectomy,
beam radiation. At SLMC, one-fourth of the patients diagnosed with
s had some tYpe of surgery as illustrated in the
the most commonly performed surger) Overall, 33% of St. Luke’s patient
).
A small percentage (3%) of patients had surgery in
ectomy
prostat
accompanying graph (74% of those patients had a radical
on). Sixty-four percent (64%) of patients with localized
combination with some other type of treatment (hormones and/or radiati
ne treatment. It is significant that although radiation
prostate cancer had radiation or a combination of radiation and hormo
al level, in 1998 at St. Luke’s brachytherapy utilization was
implant was used infrequently (<3%) in 1992 and 1995 on a nation
have any treatment.
at 40%. Of note is that only 3% of patients with local disease did not

Treatment For Local Disease
TYPES OF SURGERY
Radiation
25%

—
—

Radiation & Hormone
39%

Radical Prostatectomy
Transurethral Resection
Prostatectomy with
en bloc resection
Surgery & Other Treatment
3%
Surgeryj
30%

,Iage

-----

TYPE Of SURGICAL TREATMENT
The radical retropubic prostatectomy is the most commonly performed surgery
for prostate cancer. Indications for this surgery
include patients who have localized cancer, who are likely to be cured
and who will live long enough to benefit from the treatment.
As identified in the 1998 NCDB Annual Review of Cancer Patient Care,
trends toward diagnosis at earlier stages of disease and
younger ages support this type of curative intervention. Published statisti
cs from NCDB show that of those patients having surgely
in 1995, 66% had radical prostatectomies. Metro region data compa
res to national findings with the radical prostatectomy being
the most common type of surgery for those patients having surgerv. At
St. Luke’s Medical Center and at West Allis Memorial
Hospital, 72% and 53% of the patients had prostatectomies while at
Sinai Samaritan Medical Center only 42% had this surger’,
Of interest is that 42% of the patients at Sinai had surgery to a site other
than the primary. This could be related to the large
percentage of patients diagnosed with advanced disease.

Type Of Surgical Treatment

+

IURP with or without
LN dissection
Subtotal resection ot prostate
with or without LN dissection

•
1

—

Radical prostatectomy with
or without LN dissection
Radical cystectomy with
or without LN dissection
Surgery NOS / Unknown Type!
Regional or Distant Site
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PRO STATE

Mitchell Pincus, MD

Carcinoma of the prostate is the most common cancer in men
(244,000 in 1999), and the second leading cause of cancer
deaths in men in the United States (after lung cancer). Radical
prostatectomy and external beam radiation therapy are the most
common curative modalities used in the treatment of early stage
prostate carcinoma. Recently, transrectal ultrasound guided
brachytherapy has gained popularity as an excellent treatment
option for these patients. Interstitial prostate seed implantation
is a team effort, requiring radiotherapeutic knowledge, medical
physics calculations, and urologic surgical skills. Most patients
with localized prostate cancer are eligible for seeds. However,
patients with very large or very small glands may not be.
Hormone therapy may reduce the large glands enough for
still over 50 cc’s have too high a
implantation.
However,

those

chance of pubic arch interference and/or excessive obstructive
urinary symptoms and should not be implanted. Patients with
other severe medical problems that could pose unacceptable
operative risks or those with life expectancies less than five
years are not candidates for seeds. Patients with prior TURP’s
(transurethral resection of prostate) with large residual defects
or those with involved lymph nodes, metastatic or 13 disease
should not receive seeds. Brachytherapy should be tailored to
the individual patient’s prognostic factors. Patients with high
Gleason’s grades (greater than or equal to 8), high PSA’s
(greater than or equal to 10), or larger tumors (T2b) should
be treated with induction limited external beam radiation
therapy This would include 4500 cGy over five weeks to treat
the tissues around the prostate and kill potential microscopic
extracapsular extension.
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This may also be combined with induction

the implant. Viagra is usually helpful in those

“adjuvant” hormonal ablative therapy. The

patients. Rectal complications are also rare but

procedure is done as an outpatient through

around 2 to 5% of patients may have some rectal

Same Day Surgery. Patients receive general

bleeding that is usually self-limited. We have done

or spinal anesthesia.

almost 450 patients since 1994. Our results echo

They are placed in an exaggerated lithotomy
position and radioactive 1-125 or Pd-103 seeds
are inserted transperineally with transrectal

the 10-year national results with an overall 85 to
90% biochemical free survival. Salvage therapy is
usually hormonal therapy, as local prostate only
failures are rare.

ultrasound, ftuoroscopic, and template guidance.
The procedure is based on a preimplant

Determination of optimal therapy for clinically

ultrasound volume study done by the urologist

organ confined prostate cancer must await results

and planned b radiation oncology. The implant

of well controlled prospective studies. However,

takes about one hour. Most patients go home that

prostate seeds offer most patients with localized

same day without a Foley catheter. Ninety percent

prostate cancer a relatively easy, and effective

of patients will experience an increase in their

alternative to surgery or fractionated external

obstructive and irritative symptoms, such as

beam radiation therapy.

urgency, dysuria, and frequency. It is usually mild
to moderate, but 10 to 20% will have more severe
symptoms. These usually last from one to three
weeks; however, it can last six to eight weeks and
5% of patients may have longer term duration of
six months plus. Five percent of patients may

experience prolonged urinary retention and may
require intervention.
Incontinence is rare (1 to 2%), but may be
increased slightly (5 to 10%) in patients with
prior TURP’s. Impotence should occur in less
than 20% of patients that were potent prior to

I
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RADIATION THERAPY
St. Luke’s Medical Center 199$
—

The 1998 NCDB Annual Review of Cancer Patient Care identifies brachytherapy (interstitial implantation / seed implants) as
a ‘growing phenomena.” Although this treatment modality was used infrequently in 1992 and 1995, the proportion of patients
having seed implants increased on a national level from 1 .4% to 2.2%. In comparison, St. Luke’s Medical Center had a much
higher rate of usage with 8% of its patients having this type of treatment in 1995. Additionally, 11% of patients had brachytherapy
in combination with external beam radiation during that year. In 1998 the percentage of patients having brachytherapy increased
to 40%, and 9% had combination treatment (seed and external beam). As can be seen in the graph insert, the majority of patients
treated with brachytherapy had iodine seed implants. Note that the data depicted in the accompanying graph includes five patients
having regional or distant disease who were also treated with beam radiation.

Radiation Therapy
RADIATION THERAPY

BRACHYTHERAPY
1%

Combination Beam
with Implants

26%

Brachytherapy

t’..

Iodine
— Palladium
—

— Other Interstitial
— Iridium

NoRadiationTx
40%
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Beam Radiation
11%

PROSTATE

Steve Belanger, BS, CMD

SEED

IMPLANTS

A dosimetrist is used to living behind the scenes. They have intense
patient involvement during a person’s course of radiation therapy,
but not much direct patient contact. Most people undergoing
external radiation therapy or radiation implants probably do not
even know they exist.
But they do exist. The job of the dosimetrist is to map out the course
of treatment using CT data or patient measurements. They calculate
the amount of time necessary to treat each treatment field, calculate
the doses that critical structures will receive, and in the case of
prostate seed implants, they use the information gathered in a volume
study to determine the seed placement and seed activity to give an
optimal implant.
Prostate seed implant patients will have a volume study performed
about one month prior to their implant date. In a volume study,
the patient is positioned the same as they will be for the implant
itself, and pictures of the prostate are taken using a rectal
ultrasound probe. Once a patient has had his volume study, his
only job is to wait until his implant date, which can be difficult
enough. But,

is now time for the dosimetrist to go to work and
plan the implant. The images obtained in the volume study are
it

axial images, similar to if you had sliced the prostate apart every
5mm from top to bottom. These images are fed into a planning
computer. The ultimate goal is to deliver the target dose to the
prostate itself, and have a minimal dose reaching the bladder and
rectum. Certain seed placement guidelines must also be followed.
Seeds cannot be placed directly in the middle of the prostate,
as they will probably end up in the urethra and lost. Also, the
anterior portion of the prostate is close to blood vessels which
we try to avoid.
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The posterolateral sections of the prostate are
close to nerve bundles which control potency
The dose to these bundles should be kept low
if potency is still an issue to the patient. The
dosimetrist also tries to avoid planning too
many seeds in the posterior section of the gland
because the rectum abuts the prostate posteriorly
and is a critical structure. The seeds cannot be
too close together or too far apart or there may
be areas that receive too high or too low a dose.
Tailoring the implant to each individual is an art
in addition to a science. Since no two people have
the same exact prostate, each implant will be
different. For a particular patient, the dosimetrist
will generally run several different plans and
the physician will choose the one he feels is
the most optimal. A radiation physicist doublechecks the plan for accuracy, and finally, seeds
are ordered from a supplier.
On the day of the implant, the dosimetrist will be
in surgery an hour before the case is set to begin,
loading seeds into the needles in accordance with
the plan. He or she will also be present during the
surgery directing the physicians as to where each
needle will be placed. Once the patient has been
implanted, the dosimetrist must account for every
seed, whether it was used for the implant or not.
He or she will document where each seed was
placed and will keep a record of seeds not used.
They must therefore be well versed on the
regulations of the Nuclear Regulatory
Commission in regard to personnel exposure
to radioactive materials, seed storage, and
proper documentation.

Once the implant has been completed, the
dosimetrist still has work to do. Prostate seed
implant patients all receive a modified CT scan
through the prostate gland about one month after
their implant. The dosimetrist will enter this study
into the planning computer and generate a dose
map showing the exact doses that were actually
delivered from the implant. This is very important,
since if, for whatever reason, the implant were
felt to be inadequate, additional seeds might be
added or additional external radiation delivered.
Generally there are always between twenty and
forty patients who are in the process of their
prostate implant; awaiting their volume study,
awaiting their implant, or awaiting their post
planning. Those of us working as dosimetrists may
only have a passing interaction with any of these
patients but are very proud of the work that we do
behind the scenes to make each prostate implant
a success.

TREATM F NT

OF

INC ONTIN EN CE

an.dL...sex,uai......dLy...s.fun.cti.o...n1
Stuart W. Fine, MD

There are two potential side effects that will resul
t from treatment
for prostate cancer. Those are incontinence, meaning
the involuntary
loss of urine and erectile dysfunction or the inability
to maintain an
erection which is adequate for intercourse.
Radiation therapy, either permanent prostate seed impl
ant or
external beam radiation, can result in inflammation. This
inflammation
can damage the nerves and blood vessels essential for
normal
erection function. This effect may occur immediately
after therapy
or may occur gradually over a period of time and this
issue must be
addressed in any man who is considering therapy for
prostate cancer.
Surgery, or the operation commonly known as radical
prostatectomy,
may also damage the neurovascular bundle; in fact,
in some cases
the neurovascular bundle may have to be removed in
order to remove
an extensive cancer that is involving these structures
. If possible, the
nerve and blood vessels may be spared and this is known
as a nerve
sparing radical prostatectomy. Even when a nerve
sparing radical
prostatectomy is performed and even when the most
sophisticated
technology known as Cavermapping is used to iden
tify these
structures during surgery impotence may occur. The
post surgical
inflammation and scarring may damage these structures
as well,
even though they have been identified and spared durin
g a procedure.
In essence loss of potency may result from any treat
ment for prostate
cancer and while it is certainly higher with surgery it
can occur with
both radiation and surgery
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Fortunately we are able to offer patients therapy
for this loss of function and a variety of therapies
are available. The most commonly used therapy
would be oral medication using the drug,
Sildenafil (Viagra). ft is highly effective in
restoring potency in both the radiation and
surgical patient. Another mode of therapy is
injection therapy, which allows the patient to
inject a medication into the penis, which allows
the blood vessels to dilate and bring blood flow
into the penis. Vacuum erection devices are also
useful. In cases where all other measures fail the
use of the penile implant is an excellent option
for restoring potency

A majority of the time this problem can be
addressed using medications which relax the
muscle of the bladder wall. In the rare cases
when the bladder muscle is severely damaged
and conservative treatment with antispasmodics
is not affective, the use of an electronic stimulator
known as the Interstim has shown promise
reducing severe and intractable urgenc This
device is similar to a heart pacemaker and is
attached to the nerve fibers that stimulate the
bladder. Fortunately, the
who are
affected by post radiation urgency benefit from
simple antispasmodic medications. In extreme
where the bladder is damaged and is unable
majority

cases

artificial bladders
which
be created, The
bladder
known the ileal conduit, which
constructed out of a portion of the patient’s
intestines. Other varieties of urinary diversion
diversions.
known
to

If any man feels that the quality of his life is
diminished by his loss of sexual potency, this
function can be restored with one of the
methods that have been previously discussed.
The second issue that men must deal with is
incontinence. Incontinence is the involuntary
loss of urine and there are two types of
incontinence which may result from treatment
for prostate cancer.
The first is urgency incontinence, which means
the loss of urine that is associated with the
intense urge to empty one’s bladder. This is the
type of incontinence that may occur as a result
of inflammation to the bladder as a result of
radiation therapy. In most instances the irritation
however, in some
of the bladder is
cases it may be an ongoing problem.
temporary;

of men

retain

any

volume

can

of urine,

most

common

is

as

operations,

as

continent

is

of

a

urinary

The second type of incontinence is known
stress incontinence. This type of incontinence
is the involuntary loss of urine with coughing,
sneezing or straining or simply the passive loss
of urine when a man performs any normal
as

activities

type

such as walking,

of incontinence

radical
urinary

occurs

which may

prostatectomy

sphincter
radical

is

tone.

after

running,

a

result

The

etc.

occur

This

after

external
that this

of poor

percent

prostatectomy varies.

The first treatment is to instruct the pati
ent in
exercises to help strengthen this voluntary
sphincter
muscle combined with some simple med
ications
that are known as decongestants, also know
n as
alpha stimulating drugs.
If simple exercises fail to control urinary
incontinence as a result of radical prostatec
tomy,
other options are available which include
external
clamp devices, which simply compress
the man’s
urethra and of course, the use of the artifi
cial
urinary sphincter.

Once again, the problem of post surgical
incontinence
can be addressed and resolved in any man
who is
committed to improve the quality of his
life should
this problem occur as a result of radical pros
tatectomy.
In summary, the problems of incontinenc
e and
erectile dysfunction that may occur as
a result of
the therapy for prostate cancer can be cor
rected
with a variety of techniques. No man shou
ld feel
that he must live with either of these prob
lems,
help is available. If either of these problems
occurs
as a result of treatment for prostate can
cei the
patient should seek consultation with a
urologist
who has experience in dealing with thes
e situations.
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CURRENT

ASPECTS

OF

hormonal treatment
Urology Associates, Ltd, SC

Six decades ago Huggins and Hodges established that the initial

growth of prostate cancer (CAP) is dependent upon testosterone.

Brian P. Butler, MD, FACS

Since then the standard primary treatment for metastatic prostate
cancer has been androgen suppression in the form of medical or
surgical castration. Although such androgen suppression results
in tumor responses in more than 80% of patients,

it

is not curative.

Eventually in all patients who do not die of unrelated causes, the
disease progresses, as manifested by rising concentrations of
prostate-specific-antigen (PSA), local or distant tumor growth,
and symptoms such as bone pain or urinary obstruction.

Options for Hormonal Therapy
Several different hormonal suppression approaches can benefit
men with various stages of CAP. These include bilateral orchiectomy,
estrogen therapy, LHRH agonists, antiandrogens, ketoconazole,
and aminoglutethimide.
Benefits of bilateral orchiectomy include ease of the procedure,
compliance, its immediacy in lowering testosterone levels, and
low cost. Disadvantages include psychological effects, loss of
libido, impotence, hot flashes, and osteoporosis.
Estrogens (DES) at a dose of 3 milligrams per day will achieve
castrate levels of testosterone. Similar to orchiectom estrogens
cause a loss of libido and impotence. Gynecomastia can be
prevented by low dose radiation to the breasts. However, estrogen
is seldom used today because of the risk of serious side effects
including myocardial infarction, cerebrovascular accident, and
pulmonary embolism.
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LHRH agonists, such as leuprolide, goserelin and

buserelin will lower testosterone to castrate levels.
LHRH agonist can cause impotence, hot flashes
and loss of libido. Tumor flare reaction may occur
transiently and can be prevented antiandrogens
by
at low dose for several weeks. The high effectiveness
and excellent patient acceptance of these agents
have made them the mainstay of treatment at this
time. A long term LHRH Implant that can maintain
medical castration for up to 30 months in
metastatic PCA has been developed.
Antiandrogens of various forms block the
peripheral action of testosterone. The pure
antiandrogen flutamide may cause diarrhea,
breast tenderness, and nausea. There have
been case reports of severe hepatic toxicity.
Bicalutamide may cause nausea, breast
tenderness, hot flashes, loss of libido, and
impotence. The steroidal antiandrogen megestrol
acetate suppresses androgen production
incompletely and is typically not used initially.
Long term and/or high dose ketoconazole can
induce adrenal insufficiency, pruritis, nail changes
and impotence. Aminoglutethimide commonly
causes sedation and skin rashes.

Metastatic Disease
In the 1980’s it was proposed that the anti tumor
effect could be improved by the addition of an
antiandrogen to castration. This approach was
termed combined androgen blockade (CAB), the
fundamental premise of which is that adrenal
sources of androgens contribute to CAP progression.
Antiandrogens competitively inhibit the binding of
testosterone or its metabolite to the androgen
receptor in target cells. Many randomized trials

have compared some form of CAB with castration
alone, but have produced contradictory results.
As such CAB remains controversial. A recently
updated Prostate Cancer Trial Group meta
analysis including 27 mature trials and over 8000
men with advanced prostate cancer was reported
in Lancet. This analysis found that at 5 years
CAB was associated with a slight (2%) survival
advantage when compared to monotherapy
(LHRH agonist alone). This survival advantage is
only statistically significant when trials using the
steroidal antiandrogen cvproterone acetate are
excluded. This small survival advantage must be
weighed against the quality of life and economic
impact of CAB versus monotherapy Some studies
suggest that patients treated with CAB have a
worsened QOL scores versus those on monotherapy
primarily due to diarrhea and worse emotional
function. Antiandrogens are quite expensive and
only variably covered by insurers.
Intermittent Hormonal therapy has been
advanced as a both cost effective and side effect
limiting approach to the treatment of metastatic
disease. The rationale is based on the finding that
combined androgen blockade is associated with
previously androgen-repressed genetic code for
growth factors that stimulate cancer cell growth.
If androgens are replaced, the genes remain
repressed and the tumor remains androgen
dependent. A’ temporary return of androgens (“off
therapy”) continues to suppress the growth factors
responsible for androgen independence. Pvlore
recent clinical work suggests this therapy is best
suited toward those with low tumor burden and
PSA only disease as opposed to those with overtly
symptomatic metastasis.
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patients on some
With our growing numbers of
term, an emerging
form of hormonal therapy long
is occurring.
discussion of bone density ioss
with 2000 u per
Treatment of Vitamin D deficiency
prostate cancer is
da for 12 weeks in metastatic
strength and
associated with increasing muscle
use to prevent
decreased bone pain. Biphosphonate
efit and is on
bone loss has demonstrated ben
the rise.

Neoadjuvant and Adjuvant
Hormonal Therapy

adjuvant application
More recently, neoadjuvant and
to improve
of hormones have been advanced
lly advanced or
on results for patients with loca
porting or rejecting
aggressive disease, with data sup
upon patient
hormonal therapy use depending
circumstance.
before radical
Neoadjuvant hormonal therapy
node status and
prostatectom while improving
ologic specimen,
surgical margin status of the path
in biochemical or
has not demonstrated benefit
of neoadjuvant
overall survival. As such the use
has fallen out
hormonal therapy prior to surgery
of favor.
of early adjuvant
A significant survival advantage
onstrated in
hormonal therapy has been dem
ase after radical
patients with node positive dise
cer-free survival
prostatectomy. Overall and can
with immediate
was improved in those treated
observed and
hormonal therapy versus those
The results
treated only when symptomatic.
l Research Council
confirm findings of the Medica
but conflicts with
and data from the Mayo Clinic,
trials will address
VACURG data. Future clinical
this issue.
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demonstrated
A growing number of studies have
t hormonal
the benefit of neoadjuvant and adjuvan
rnal beam and
therapy with radiotherapy, both exte
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Gleason score >7 an improvement
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with EBRT.
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LHRH agonist use in this setting
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Second Line Hormonal Therapy

awal effect
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bined androgen
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independent patient. It is also
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that all antiandrogens are not
g of the same
mechanism of action, despite bein
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drug (nonsteroidal) class. The
to antiandrogen
ketoconazole or aminoglutethimide
an increase in PSA
withdrawal has demonstrated
. Prednisone
response from 20-30% to 50-60%
e and also reduce
may be symptomatically effectiv
taking PC-SPES
PSA. A number of patients are
line therapy. A
whether as primary or second
components of
recent publication analyzed the
contain a number
this compound and found it to
of estrogenic compounds.
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Both its therapeutic effect (decreasing PSA) and

cells manipulate and redirect the cells growth

its adverse effects (DVT, CHF, gynecomastia) are

cycles into more disciplined pattern is attractive

consistent with this finding.

and ongoing.

A great deal of interest has centered on the

Hormonal therapy in the management of prostate

development of strategies for disease, which

cancer represents a diverse group of techniques

no longer responds to hormonal manipulation.

and compounds with variable effects. The optimal

Cliemotherapeutic agents are being reimrestigated

application of both type and timing of therapy to

with results. Interest in cytostatic (versus
cytotoxic) agents which rather than destroy

specific patients is an ongoing challenge.

TREATMENT BY MODALITY
One of the major trends identified in the NCDB 199$ Annual Review of Patient Care was a greater rate of treatment with curative
intent by radical prostatectomy or radiation therapy. As illustrated in the graph, over 60% of patients were treated with either
surgery or radiation alone, both at the Metro level and nationally. The exception was at Sinai Samaritan where 29% of patients
were treated with surgery or radiation alone. Of interest is that a much larger percentage of patients at Sinai Samaritan (24%)
were treated with hormone therapy alone than at St. Luke’s (7%), West Allis Memorial (6%) or at a national level (8%). This could
be due to a larger percentage of patients being diagnosed with late stage disease at Sinai Samaritan (57%) compared with St. Luke’s
(31%), West Allis (22%) or the National Cancer Data Base (21%). In addition, a large percentage of patients at Sinai Samaritan
(24%) had no known treatment.

Treatment By Modality

SLMC
Late Stage Disease

SSMC

WAMH

NCDB
0%

20%

40%

60%

0%

20%

. Alone
Surgery

40%
Radiation
Alone

60%

80%

Hormone
Therapy Alone

Page

35

CHEMOTHERAPY

Ronald D. Hart, MD

FOR

For patients whose prostate cancer has spread to the adjacent
tissues, or to distant sites, the most commonly used systemic
treatment is hormonal. Initially this was accomplished by surgical
castration, later by the use of estrogen. More recently the
treatments have been based on much less toxic regimens of
lu teinizing hormone-releasing hormone agonists (such as leuprolide
or goserelin) and nonsteroidal antiandrogens, such as flutamide
(Eulexin), biclutamide (Casodex), or nilutamide (Anandron).
Antagonists of gonadotropin-releasing hormone (GnRH), such
as abarelix are currently under development.’ None of these
treatments are curative however, and sooner or later, the patient

will develop symptoms from progressive tumor growth. The best
management for this situation is still being defined.
Many consider the combination of mitoxantrone and prednisone
to be the standard of care, since two randomized trials have shown
a palliative benefit.2’3 A significant survival advantage was reported
in October 2000 for men with locally advanced prostate cancer
who received adjuvant mitoxantrone chemotherapy plus hormone
treatment compared with men who received hormone treatment
alone

.“

Estramustine is an estrogen linked to a non-nitrogen mustard.
When it is combined with vinblastine or oral etoposide it leads to
PSA declines of 50% or more in 45% and 52% of patients respectively.
Objective responses are seen in 26% and 33% of these patients. A
randomized comparison of vinblastine with or without estramustine
showed a trend to improved survival for the combination, and a
statistically significant improvement in time to progression

3

—.———....—.——

The most recently developed class of drugs for
prostate cancer are the taxanes. The combination
of estramustine plus paclitaxel led to a PSA
response rate of 52%, and objective responses
were observed in 44% of patients with measurable
soft-tissue lesions.
The median survival reported in this study of
patients with hormone refractory disease was
17 months.6 In a phase I study of estramustine
combined with docetaxel in men with hormonerefractory prostate cancer, 62% of patients treated
had a PSA decline of 50% or more; objective
responses were observed in 28% of patients.
Of the patients with bone pain requiring
narcotic medications, 53% discontinued all
pain medications for a median of 6 weeks.
The median survival reported was approximately
23 months.7
The combination of estramustine and docetaxel
is now being compared in a randomized trial with

1. McLeod D, Zinner N, Gleason D, et al. Abarelix-Depot
versus leuprolide acetate for cancer patients: results of
a multi-institutional, randomized phase III study in 271
patients. Program and abstracts of the American Society
of Clinical Oncology 36th Annual iVleeting; May 20-23,
2000; New Orleans, Louisiana. Abstract 1306.
2. Tannock IF, Osoba D, Stockier MR, et al.
Chemotherapy with mitoxantrone plus prednisone or
prednisone alone for symptomatic hormone-resistant
prostate cancer: a Canadian randomized trial with
palliative end points. J Clin Oncol. 1996;14:1756-1764.
3.Kantoff PW, Halabi 5, Conaway M, et al. J Clin Oncol.
l999;17:2506-2513.
4. Waxman

J. et al. Brit J Urol lnt 2000;86:675-680
5. Hudes G, Einliorn L, Ross E, et al. \Jinblastine versus
vinblastine plus oral estramustine phosphate for patients
with hormone-refractory prostate cancer: a Hoosier
Oncology Group and Fox Chase Network phase III trial.
J Clin Oncol. 1999;17:3160-3 166.
6. Hudes GB, Nathan F, Khater C, et al. Phase II trial
of 96-hour paclitaxel plus oral estramustine phosphate
in metastatic hormone-refractory prostate cancer. Clin
J
Oncol. 1997;15:3156-3163.
7. Petrvlak DP, Macarthur RB, O’Connor J, et al.
Phase I trial of docetaxel with estramustine in
pandrogen-independent prostate cancer. J Clin Oncol.
1999;17:958-967.

the current standard therapy of mitoxantrone
prednisone. This national trial will accept 620
patients over the next 3 years and is available to
patients at St. Luke’s Medical Center. It will help
answer many of the remaining questions for
patients with advanced disease.
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AJCC STAGE
Data from the 1998 NCDB Annual Review of Prostate Cancer indicates that Stage II disease is diagnosed most frequently showing
an increase of 8.6% from 1992 to 1995. As illustrated in the accompanying graph, 1995 data from St Luke’s 1\’Iedical Center
(SLI’viC) and West Allis Memorial Hospital (WAMH) compares with national statistics, the majority of cases being diagnosed at
Stage II disease. Data from Sinai Samaritan Medical Center (SSIVIC) for that time frame differs in that the greatest number of
patients were diagnosed with more advanced Stage IV disease.

AJCC Stage Of Disease At Diagnosis
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According to the American Cancer Society’s
Cancer Facts and figures of 1992, the five-year
relative survival rate for all stages of disease was
74%. Today, the most recent Fact and figures
state that overall five-year survival has increased
to over 93%. The graph on the right represents
relative survival of cancer patients with combined
stages of disease who were reported between
1985 and 1990. Results show a comparable
benchmark outcome between patients treated
in the Metro Region of Aurora Health Care to
those reported nationally to the National Cancer
Data Base (NCDB).
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Jorge G. Pellegrini, MD

Pathology
Adenocarcinoma accounts for about 95% of prostatic malignancies.
Prostatic carcinomas can be divided into two major categories on the
basis of their presumptive site of origin and morphologic appearance:
1) adenocarcinoma of peripheral (“secondary”) ducts and acini and
2) carcinoma of large “primary” ducts. The majority belong to the
first category.

Adenocarcinoma of Peripheral Ducts and Acini
Most of these carcinomas arise in the peripheral zone, whether
posteriorly, laterally, or anteriorly, with sparing of the periurethral
region except for the late stages of the disease. Grossly, the tumor may
be difficult to see but usually can be identified as a gray or yellowish,
poorly delineated, firm area. In prostatectomy specimens, multiple
tumor foci have been demonstrated in 75

-

85% (multicentricity).

The presence of prostatic glands within perineural spaces is common
in these tumors and its presence in a needle biopsy specimen is a
good predictor of capsular invasion by the tumor.

Carcinoma of Large (“Primary”) Ducts
Microscopically, the following types have been recognized: Large
(prostatic) duct adenocarcinoma, endometrial-type (endometrioid)
adenocarcinoma, primary transitional cell carcinoma and mixed
adenocarcinoma-transitional cell carcinoma.

Other Prostatic Carcinomas
Other prostatic carcinomas exist, most of them probably representing
variants of adenocarcinoma of the peripheral ducts and acini. These
include carcinoma with neuroendocrine features, including small
cell carcinoma, mucinous adenocarcinoma, signet ring carcinoma,
adenosquamous cell carcinoma, squamous cell carcinoma, adenoid
basal cell tumor, basaloid carcinoma, and lymphoepithelioma-like
carcinoma.

9

Immunohistochemical and
Other Special Techniques

in detecting prostatic carcinoma. Poorly and

Two immunohistochemical markers for prostatic
epithelium demonstrable in routinely processed

with ease, but there is some difficulty in identifying
lesions at the better differentiated end of the
spectrum. The overall accuracy of the needle
biopsy according to one study, was 85.6%, and

material with polyclonal or monoclonal antisera
are PAP and PSA. Antikeratin antibody 34BE 12
(high molecular keratin) identifies basal cells in
the prostatic glands and is therefore of diagnostic

that of the aspirates was 86.6%; when considered

use; it is invariably present (although sometimes
discontinuously) in benign glands and absent in

figure of 95.8%. Despite these facts, aspirations

adenocarcinomas regardless of grade. Information
on the chromosomal alterations of prostatic
carcinoma is sparse. Mlelic loss has been found in
about half of the cases. Numerical chromosomal
aberrations are associated with advanced disease.
Mutations of p53 have been found in a subset of
prostatic carcinomas characterized by a highly
proliferative pattern and an aggressive behavior.

cytology has fallen into disuse (especially in
the United States) and largely replaced by the
spring-loaded 18-gauge biopsy.

Biopsy, TUR, and Frozen Section
During the last decade the automated springloaded 18-gauge biopsy gun has gained in popu
larity. One author reported a false-negative rate of
12% because of sampling error with needle biopsy

Prostatic lntraepithelial Neoplasia (PIN)
PIN is the currently preferred term for a process
involving prostatic ducts and acini, which has also

men is directly related to the amount of sampling
and can reach up to 90% of the carcinomas

been described as intraductal or ductalacinar
dysplasia. A subsequent consensus conference

detected. The accuracy of frozen section for the
diagnosis of prostatic carcinoma is high.

is the most likely precursor of prostatic
adenocarcinoma. This association refers to
high grade prostatic intraepithelial neoplasia
or PIN III. The clinical importance of recogniz

Frozen section examination and touch imprints
are also useful for the diagnosis of lymph node
metastases, but both techniques suffer from a
10% to 15% incidence of false-negative results.

Spread and Metastases

ing high grade prostatic intraepithelial neoplasia
is based on its strong association with prostatic

Invasion of the “capsule” (i.e., the outer
fibromuscular layer of the prostate) is very

carcinoma.

common in carcinomas of the prostate. In one
series, capsular invasion was found in 90%

Cytology
In experienced hands, the technique of
fine-needle aspiration cytology is very effective
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together, the accuracy reached the remarkable

of the prostate on a 4-year follow-up. The proba
bility of detecting a carcinoma in a TUR speci

sponsored by the American Cancer Society
concluded that prostatic intraepithelial neoplasia
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moderately differentiated tumors are diagnosed

of specimens from radical prostatectomies
in patients with clinical stage A or B disease.

In another study, the probability of tumor
having extended outside the prostate into the
neurovascular bundles was found to be zero if
the ‘capsular margin” was negative, 12% if it was
equivocal, and 60% if it was positive. Advanced

In general, the degree of microscopic differentiation
of the metastases and of PSA expression follows
closely that of the primary tumor.

Grading

tumor may extend into the seminal vesicles, apex
(distal aspect) of the gland, prostatic urethra
(very rarely), and bladder. Rectal invasion is

Microscopic grading of prostatic adenocarcinoma
has been found to correlate well with PAP and
PSA levels, clinical and pathologic staging,

much less common.

incidence of lymph node and bone metastases,
survival rate, and response to therapy. The grading
system developed by Gleason in conjunction
with the Veterans Administration Cooperative
Urologic Research Group has shown a remarkable
correlation with mortality rates and is currently
preferred to other grading methods proposed

The most common sites of metastatic spread
of prostatic carcinoma are the skeletal system
and lymph nodes. Bone metastases are usually
multiple, but can be solitary The most common
pathway of nodal involvement is to the pelvic
chains, from which the tumor spreads to the
retroperitoneal nodes. The overall incidence of
nodal metastases at the time of diagnosis has
been in the neighborhood of 40% in the majority
of published series, but it has been considerably

over the years. This grading system is based on
the degree of glandular differentiation and the
growth pattern of the tumor in relation to the
stroma as evaluated on low-power examination.

lower in most recent studies, suggesting a change
in the stage at which prostatic carcinoma is

According to Gleason’s system, 5 patterns are
defined (1-5) and three Gleason Scores are

currently diagnosed.

determined: 2-4 Well-differentiated, 5- 7
Moderately differentiated, and 8-10 Poorly
differentiated. The patterns described are

Lumbar spine, sacrum, and pelvis are the most
common locations for bone metastases, supposedly
as the result of tumor spread via Batson’s vertebral
venous system. However, any other bone can be
involved through the systemic circulation. Lung
metastases are not as rare as formerly believed;
most of them exhibit a lymphangitic pattern of
spread. Prostatic carcinoma also may metastasize
to the breast, sometime bilaterally, particularly in
patients taking estrogens. Other metastatic sites
include liver, adrenal gland, central nervous
system (including dura), eye, skin, and unusual
locations such as penis, and salivary gland.

synonymous with grades. If this system is used,
the combined grade (pattern) is obtained by
adding predominant grade (primary grade or
pattern) and the other grade (secondary grade
or pattern). The pattern (grade) sum results
in the Gleason’s score.
As already indicated, the histologic grades correlate
with the clinical and pathologic stages; in addition,
grading shows good correlation with mortality rates
within each clinical stage. By combining grading
and staging, the best predictive values are obtained.
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Prognosis
From the pathologic point of view; many parameters
have been evaluated for their ability to predict

surgical margins, tumor volume, PSA and PAP
immunoreactivit) neovascularity, neuroendocrine

outcome in patients with prostatic carcinoma,
as follows: pathologic stage, microscopic grading,

features, androgen-receptor status, DNA p1oid3
chromosomal abnormalities, p53 expression and
ras oncogene.

HISTOLOGIC CELL TYPE
in its data regarding tumor characteristics of prostate cancer patients, the National Cancer Data Base describes histologic cell
type as referring to the type of cell or tissue in which the cancer has formed. Cell types differ in patterns of spread and treatment
characteristics. According to the “Textbook of Clinical Oncology” the vast majority of prostate carcinomas are adenocarcinomas.
This is further detailed by the National Cancer Institute in its CancerNet Service which indicates that 95% of primary prostate
cancers are adenocarcinomas. As can be seen in the accompanying table, metro statistics for 1995 support this and compare almost
equally to NCDB data with the exception of Sinai Samaritan Medical Center where approximately 86% of patients were diagnosed
with adenocarcinoma.

Histology
SLMC

SSMC

WAMH

NCDB

Adenocarcinoma NOS

95.5%

85.7%

95.2%

96.0%

Acomar cell carcinoma

1.5%

2.0%

2.0%

Carcinoma NOS

3.0%

2.0%

2.0%

0.7%

Carcinoma in situ

R

14.3%
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TUMOR GRADE
St. Luke’s Medical Center

—

199$

The Gleason Grading System is the most commonly used
system for grading prostate cancer. After a biopsy the tissue
is examined to determine how closely the cancer cells look
like normal tissue. Prostate cancers often have areas with
differentiated grades, so the pathologist assigns a primary
grade and a secondary grade, ranging from I through 5, to
each of the two largest areas of cancer in the tissue sample.
The grades are then added to produce the Gleason score. A
score of 2-4 is considered low grade (well-differentiated), 5-7
intermediate grade (moderately differentiated) and 8-10 high
grade (poorly differentiated). The higher the grade, the more
aggressive the cancer is. Tumor grade is useful as a predictor
of outcome. The Gleason grade along with PSA and clinical
stage provide a basis for predicting behavior and making
treatment decisions.

Tumor Grade

6%

7%
GLEASON GRADING SYSTEM

At St. Luke’s Medical Center during the year 1998, the
majority of prostate cancers were moderately differentiated
(69%) which compares to NCDB data from 1995 (62%). The
most commonly performed biopsy done at St. Luke’s was the
ultrasound needle core biopsy, transrectal approach.

—
—
—
—

Well-Differentiated (Scores 2/3/4)
Moderately Differentiated (Scores 5/6/7)
Poorly Differentiated (Scores 8/9/10)
Unknown

AJCC LOCALIZED DISEASE
St. Luke’s Medical Center

—

1995

The 1998 NCDB Annual Review of Prostate Cancer
indicates that patients are being diagnosed at earlier
stages and that the number of patients diagnosed with
localized disease (Stages 0, 1 and II) has increased.
The NCDB Review reports an increase of 7.4% in
the proportion of patients diagnosed with localized
disease from 1992 to 1995. Data from hospitals in
the Metro Region for 1995 shows the number of
patients diagnosed with local disease comparable
to that of the NCDB with the exception of Sinai
Samaritan which was 26% lower than the national
average (SLMC 68%, SSMC 43%, WAMH 68%,
NCDB 69%). The Metro Region average for localized
disease was 60%.

AJCC Localized Disease
100%
80%
60%
40%
20%
0%

SLMC

SSMC

WAMH

NCDB

RECENT

ADVANCES

IN

p..r.c.state.c..a.n.c..e..r..........g.e.n.e.U.c.s.
Angela Mengelt, MS

Prostate cancer is an important issue in men’s health. Each year, over
180,000 new cases are diagnosed and 32,000 deaths are attributed to
the disease. Key risk factors for prostate cancer include age and race.
Three-quarters of prostate cancers will be diagnosed in men over the
age of 65 and the incidence of prostate cancer in African-American
men is significantly increased above that of Caucasian men.’ As with
many other cancers, such as breast, ovarian, and colon, another
important risk factor for prostate cancer is family history.
The association between increased prostate cancer risks and a positive
family history for the disease has been well documented.2’34 A casecontrol study of 691 men with prostate cancer found that men with
one, two, and three first-degree relatives with prostate cancer were
two, five, and eleven times as likely to develop prostate cancer,
respectively, as compared to men with no family historyc2 The risk
of developing prostate cancer is further increased when the diagnoses
in the family are made at an early age. For example, in studying
father/son pairs with prostate cancer, Gronberg et al. assessed
cumulative risks to unaffected sons based on this family history and
age at diagnosis of the father. Overall, they found the cumulative risk
for prostate cancer in sons to be 5%, 15%, and 30% by ages 60, 70,
and 80 respectively and the risk to be 25% and 43% by ages 60 and
70 respectively when the father was diagnosed before age 70.
Hereditary prostate cancer is defined as three first-degree relatives
with prostate cancer, three generations in the same family line
affected with prostate cancer, or two first-degree relatives with
prostate cancer under the age of 55. Much effort has been made to
define the genetic factors that play a role in these hereditary prostate
cancer families. Complex segregation analyses have suggested
autosomal dominant inheritance of a rare, highly penetrant allele.

This allele is thought to have a frequency of
0.3% in the general population and account
for 9% of all prostate cancers and 40% of
prostate cancers under the age of 55 6 X-linked
or autosomal recessive inheritance has also been
suggested by one study as the risk for prostate
cancer in individuals with affected brothers
was greater than the risk in individuals with
affected fathers.7
Utilizing high-risk prostate cancer families,
several groups are now searching for putative
prostate cancer predisposing genes. Thus far,
no prostate cancer genes have been cloned,
but several regions of the genome have been
identified as potential candidates for possessing
such genes. In 1996, Smith and others performed
a genome-wide scan in 66 prostate cancer families
with 3 or more first-degree relatives with prostate
cancer. They identified a prostate-susceptibility
locus, HPC 1, on the long arm of chromosome
1 (1q24-25).8 Since this initial study, other
potential loci have been identified including
HPCX (Xq27-28), PCAP (lq42.2-43), and
HPC2O (2Oq13) in prostate cancer families
and CAPB (lp36) in families with prostate and
brain cancers.9”°”2 For each potential locus,
confirmation studies have provided conflicting
results.’3”4’5”6”7 Therefore, hereditary prostate
cancer appears to possess significant locus
heterogeneity with multiple genes each accounting

Increased risk for prostate cancer has also been
associated with other cancer syndromes and
modifier genes. The risk for prostate cancer is
increased in males with mutations in the hereditary
breast and ovarian cancer genes, BRCA1 and
BRCA2.’8”9 Mutations in these genes, however, are
infrequently identified in prostate cancer only
families and are unlikely to play a significant role
in hereditary prostate cancer.20’21 An example
of a modifier gene that may play a role in prostate
cancer risk is the androgen receptor gene (AR) on
the X chromosome. The binding of androgens to
the androgen receptor gene results in its activation
and ability to activate the transcription of other
genes. The AR gene contains a polymorphic CAG
trinucleotide repeat in the first exon. Shorter
repeats are associated with increased transcriptional
activity of the AR gene. As prostate cancer
depends on androgens, it has been suggested
that shorter repeats would be associated with
increased risk for prostate cancer. Studies have
shown that CAG repeats are, on average,
shorter in African-American individuals than
in Caucasians perhaps corresponding to the
increased incidence of the disease in the African
American population. Another study demonstrated
a 3% increase in the risk of prostate cancer with
each single decrease in the number of CAG
repeats.ni 22

for a small proportion of hereditary prostate
cancer families.
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With increasing popular press addressing the role
of genetics in cancer, the population is becoming
more and more interested in personal cancer risk

assessment. High-risk clinics designed to assess
risks for prostate cancer and provide comprehensive
medical management have already been developed.25
The identification of hereditary prostate cancer
families allows for the education of the consultant
and other family members regarding their risks
and surveillance strategies.
Current recommendations for men from high-risk
prostate cancer families include digital rectal
exam and prostate specific antigen annually
beginning at age 40. Although prostate cancer
susceptibility genes have not yet been cloned,
two studies have addressed the interest in genetic
testing for prostate cancer. Both studies suggested
a strong interest and high uptake of genetic testing
for hereditary prostate cancer.2324
In summary the genetics of hereditary prostate
cancer appear to be complex. There are likely to
be several patterns of inheritance and multiple
genes implicated in the syndrome. With the
completion of the Human Genome Project,
prostate cancer susceptibility genes will likely be
cloned in the near future and clinical genetic
testing for hereditary prostate cancer will
inevitably be developed. This will allow for
improved identification and risk assessment of
high-risk individuals and families. Once identified,
these individuals can be counseled regarding
increased surveillance in hopes of reducing
mortality from this disease.
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Key risk factors for prostate cancer are age, race and family historv. Current information from the National Cancer institute
indicates that 75% of prostate cancers are diagnosed in men ages 65 and older and that African-American men have the
highest incidence of prostate cancer world-wide. In addition, risk increases for men who have a father or brothers diagnosed
with this disease. If a man has three relatives with prostate cancer, the risk is more than ten times greater. factors such as
hormones, diet, environmental exposures and other lifestyle changes are increasingly being studied as to how they max’ relate
to prostate cancer. As shown in the accompanying chart, in 1998 at St. Luke’s Medical Center, 66% of the patients diagnosed
with prostate cancer were age 65 or older, 9% had first degree relatives diagnosed with this disease, and 5% of the patients
were of African-American descent.

Risk Factors

Key Risk Factors
(total 174 patients)

FAMILY HISTORY

RACE

Age
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end of life care
Visiting Nurse

The Visiting Nurse Association of Wisconsin Hospice provides a
specialized, family centered oncology program for end-of-life care.

Association of Wisconsin

Although most hospice care is provided in patients’ homes, the VNA
also cares for patients in assisted living centers, nursing homes and

Mary Runge, RN, MBA

hospitals. Recently, the Milwaukee Hospice Residence became part
of the VNA. It’s a seven-bed residential facility for people who desire

Director VNA Hospice

a home-like atmosphere, but can no longer remain in their own
home. VNA Hospice is one of only a few hospices in Wisconsin that
also offers a pediatric program.
The VNA Hospice team works in collaboration with the patient’s
own physician to focus on pain management, symptom control,
comfort and care. The team is comprised of the Hospice medical
director, nursing, social services, spiritual counselors, rehabilitation
therapy, IV and respiratory therapy, home health aides and volunteers.
During the past year, the number of oncology-certified VNA nurses
has increased by 1 50%.

The VNA is always seeking ways to expand and support the continuum
of care offered to patients and staff of the Vince Lombardi Cancer
Clinics. Of the more than $0 hospice patients we visit each month,
88% have been diagnosed with cancer. For those patients who come
to the Vince Lombardi Cancer Clinics from outside the Milwaukee
area, the VNA is able to continue their care when they return home
anywhere in Eastern Wisconsin. Hospice services have recently
been extended to the far north with the licensure of our Sturgeon
Bay branch.

As the goals of treatment turn from cure to
comfort, the patient’s physician will determine
when it is appropriate to transition to hospice
care. Since Medicare coverage for hospice care
often exceeds that for home health care it is in
the patient’s best interest to be referred to hospice
early on, rather than in the final days or weeks
of life. Hospice is covered through I\’Iedicare,
Medicaid, private health insurance, and private
resources. Social work staff assists in accessing

Grief counseling and support groups assist the
family during and after the loss of a loved one.
These services continue for a full year.
The Visiting Nurse Association of Wisconsin
oncology program is designed to center around
the patient and their family. The specially trained
Hospice team provides physical, emotional and
spiritual care, helping the patient to live out their
life with meaning and dignity.

and utilizing all available reimbursement.

For more information about the VNA’s oncology

Contributions to the Visiting Nurse Association

program, hospice care and pain management,

Fund assist patients who do not have the

contact Mary Runge at 414-438-8000.

resources to pay for hospice services.
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Pre-clinical Research Study to
Evaluate the Potential for PSMA
Specific I cells as Therapy for
Patients with Prostate Cancer
Nina K. Garlie, PhD
Ann V LeFever, PhD

In patients with cancer, T cells are not present in
sufficient numbers to kill the tumor, or the T cells
that are present are dysfunctional. Therefore, the
tumor grows (See Figure 2).

This is a research study being conducted by Nina
K. Garlic, Ph.D. and Ann V. LeFever, Ph.D. of the
Immunotherapy Program at St. Luke’s l\’Iedical
Center.

Purpose
Prostate-specific membrane antigen (PSMA)
is a protein that is present at high levels on the
surface of prostate cancer cells. We have obtained
purified PSMA from Northwest Biotherapeutics,
Inc. (Seattle, WA). It will be used to optimize
a method of generating prostate-specific killer
immune cells in the laboratory. The information
obtained from this research will help us to develop
new therapies for patients with prostate cancer.

Figure 2. Tumor cells (40X).
Dendritic cells (DCs): In recent studies, dendritic
cells (DCs) (See Figure 3) have been used as an
efficient approach to stimulate tumor-specific T
cells in the laboratory. DCs are present in blood
and have the capacity to uptake tumor protein
and process it. These tumor protein-loaded DCs
can efficiently stimulate T cells to kill tumors.

Background Information
T cells: T cells are a type of immune cell that are
present in blood and are necessary to fight cancer
(See Figure 1).

Figure 3. Dendritic cells (40X).

Figure 1. T cells (40X).

1aae

SOb

PSMA: The tumor protein to be used in this study
is PSMA. PSMA is over-expressed by a large
proportion of prostate cancers 1 and is very highly
expressed in higher-grade prostate cancer, in
metastatic disease 1 and in hormone-refractory
prostate cancer.’3 Clinical responses have been
observed in patients with advanced prostate cancer
after vaccination with PS MA-loaded DCs.46

Methods
The ability to generate prostate-specific T cells in
the laborator from the blood of healthy individuals
as well as patients with prostate cancer has been
demonstrated.79 In our stud T cells from the
blood of patients with prostate cancer will be
stimulated in the laboratory with their own DCs
loaded with PSMA. A method of non-specific
T cell expansion will be optimized to expand the
T cells to numbers that will be required for therapy.
The specificity and activity of the responding
T cells will be monitored using
that measure

3. Phase I/Il trial to test the safety and efficacy of
PSMA-specific T cell therapy in combination with
other immunotherapy including vaccination with
tumor antigen-loaded DCs.
Reference List
1. Wright, G.L., Jr., Haley, C., Beckett, M.L., and
Schelihammer, P.F. Expression of prostate-specific membrane
antigen in normal, benign, and malignant prostate tissues.
Urol.Oncol., 1: 18-28, 1995.
2. Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R., and
Heston, WD.W. Expression of the prostate-specific
membrane antigen. Cancer Res., 54: 1807-1811, 1994.
3. Maraj, B.H., Whelan, P., and Markham, A.F. Prostate-spe
cific membrane antigen. Br.J.UroI., 81: 523-528, 1998.
4. Tjoa, BA., Erickson, S.J., Bowes, V.A., Ragde, H., Kenny,
G.M., Cobb, O.E., Ireton, B.C., Troychak, M.J., Boynton,
A.L., and Murph G.P. Follow-up evaluation of prostate
cancer patients infused with autologous dendritic cells
pulsed with PSMA peptides. Prostate, 32: 272-278, 1997.
5. Tjoa, BA., Simmons, S.J., Elgamal, A., Rogers, M., Ragde,
H., Kenny, G.M., Troychak, M.J., Boynton, A.L., and
Murphy, G.P. Follow-up evaluation of a phase 11 prostate
cancer vaccine trial. Prostate, 40: 125-129, 1999.
6. Murphy, G.P., Tjoa, B.A., Simmons, S.J., Rogers, M.K.,
Kenny, G.M., and Jarisch, J. Higher-dose and less frequent
dendritic cell infusions with PSMA peptides in hormone
refractory metastatic prostate cancer patients. Prostate, 43:
59-62, 2000.

assays

the ability of the T cells to kill prostate cancer
cells. The data from this study will provide the
basis for clinical trials to test the efficacy of
tumor-specific T cell therapy for patients
with cancer.

Potential Clinical Trials
1. Phase I trial to test the safety and toxicity of
PSMA-specific T cell therapy in a dose escalation

7. Pesliwa, M.V, Shi, J.D., Ruegg, C., Laus, B., and van
Schooten, W.C. Induction of prostate tumor-specific CD8+
cytotoxic T-lymphocytes in vitro using antigen-presenting
cells pulsed with prostate acid phosphatase peptide. Prostate,
36: 129-138, 1998.
8. Xue, B.H., Zhang, Y., Sosman, ].A., and Peace, D.J.
Induction of human cvtotoxic T lymphocytes specific for
prostate-specific antigen. Prostate, 30: 73-78, 1997.
9. Tjoa, BA., Boynton, A., Kenny, C., Ragde, H., Misrock,
S.L., and 1\’Iurphy, G. Presentation of prostate tumor anti
gens by dendritic cells stimulates T-ceIl proliferation and
cytotoxicity. Prostate, 28: 65-69, 1996.

trial in patients with advanced, refractory disease.
2. Phase I/Il trial to test the safety and efficacy of
PSMA-specific T cell therapy as adjuvant therapy
after surgery or radiation therapy.
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Eastern Cooperative Oncology
Group (ECOG) Studies
Nancy Briggs, RN, MSN, OCN,
Research Coordinator
Gary Shapiro, MD,
Principal Investigator

In nursing research, Sinai Samaritan Medical
Center, in collaboration with the University
of Wisconsin-Madison School of Nursing, is
conducting a randomized study addressing
medication side effects, quality of life and barriers
to pain control in outpatients with metastatic
prostate cancer and other advanced diseases.

The Medical Oncology Clinic at Sinai Samaritan
Medical Center is an affiliate of the University

This study offers 1:1 nurse-patient interaction as

of ‘Wisconsin’s Comprehensive Cancer Center

an innovative approach to cancer pain education.

(UWCCC) and the Eastern Cooperative Oncology

For more information about these studies, contact

Group (ECOG). In addition, the clinic is a charter

Nancy Briggs, research coordinator at 414-219-6591.

member of the Wisconsin Oncology Network
(WON), a newly developed statewide network of
UWCCC affiliated hospitals and clinics. Through
this network, Wisconsin’s cancer patients have
greater access to innovative investigational cancer
treatments. These include agents that have just
come out of the laboratory and are being evaluated
in humans for the first time.
Active ECOG studies include evaluation of Taxol
and oral Estramustine given weekly for patients

with metastatic hormone-refractory prostate cancer.
Patients eligible for this study have had prior
hormonal therapy with evidence of treatment
failure. In addition, an intergroup study is evaluating
continuous versus intermittent combined androgen
deprivation in newly diagnosed metastatic prostate
cancer patients. Both of these studies are assessing
quality of life concerns for patients undergoing
treatment.

I

Radiation Therapy
Oncology Group

Two studies are also available that contribute to
improving the quality of life of cancer patients.

Monique $wiecichowski, RN, BSN,
Research Coordinator
Mitchell Pincus, MD, Principal
Investigator

RTOG 98-09 is intended for patients with GI

St. Luke’s Medical Center (SLMC) has been
an affiliate member of the Radiation Therapy
Oncology Group (RTOG) since 1993. In 1998,

symptoms following the completion of radiotherapy
to the pelvis used in, among others, the treatment
of prostate cancer. This study will evaluate the
drug’s effectiveness against bowel injury evidenced
by proctitis, diarrhea and/or melena, caused by
radiation and identify side effects of the drug.

West Allis Memorial Hospital (WAMH) began

This double-blinded study randomizes patients to
one of two doses of Elmiron or placebo and does

offering RTOG protocols to their radiation

not exclude the concurrent use of medications

patients as a ‘joint center’ with SLMC. RTOG is

used for symptom management. RTOG 97-14

a multi-center organization that includes 27 full

compares a single fraction (8 Gy) to 10 fractions

member institutions and more than 180 affiliate

(30 Gy total) for palliative treatment of prostate

institutions in the United States and Canada.

cancer patients with painful bone metastases.

founded in 1968, it was organized as a national

Frequency and duration of pain relief, quality

clinical cooperative group for the purpose of

of life, cost-effectiveness, and incidence of

conducting radiation therapy research and

secondary pathologic fractures will be compared.

cooperative clinical

investigations.

The nature of cooperative groups is to evaluate
Seven new studies opened this year. New clinical
trials dedicated to increasing the survival of

and re-evaluate current standards of care. RTOG
has completed a study investigating the use of

patients with malignant diseases were made

radioactive seed implants for the treatment of

available to patients being treated for cancer of

prostate cancer. The study was designed, in part,

the anal canal, recurrent head and neck cancer,

to establish quality assurance standards for

advanced head and neck cancer, anemic head

future protocols. Once the data is evaluated, it

and neck cancer patients, and prostate cancer

is anticipated that clinical trials will be developed

patients. Clinical trials are currently available
for the treatment of prostate cancer for locally
confined, intermediate-risk, and high-risk disease,
as well as for patients with PSA elevations status
post prostatectomy

using

this method of treatment. We expect to

make these trials available to our patients as
well. For more information about these studies,
please contact Monique Swiecichowsid at
414-649-5990.
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CANCER

CONFERENCES

IN

THE

n.. e.tro n..g1on
Educational Tumor Boards
and Second Opinion Programs
for Oncology

iVlonthlv luncheon Tumor Boards are held the
third Friday of each month from 12:00 noon
to 1:00pm

Tumor Boards and Second Opinion Programs
are offered through weekly and/or monthly

• Hartford i\’Iemorial Hospital Board Room

cancer case conferences. These conferences
provide an educational and consultative forum

BREAST CONFERENCE
Weeki breakfast meetings are held each
Wednesday from 7:30 am to 9:00 am

for health care providers to discuss newly diagnosed
cancer cases.
The consultative forum, allows physicians to bring
forth a variety of cancer cases that are different

• St. Luke’s i\’Iedical Center HS3
FJ

Monthly luncheon meetings are held from
12:00 noon to 1:00 pm

and unique each week. An overview of the
diagnostic findings is followed by a professional

• Sinai Samaritan Medical Center 4th Friday
of each month Rapkin Auditorium

and consultative dialog among multispecialists.
The outcome consists of recommendations that
lead the way for ctbest practice patterns of

• West Allis 1’vlemorial Hospital 1st Friday
of each month in Conference Room A/B

treatment. It is important to note that patient
names are always withheld to protect a patient’s
confidentiality and privacy.
The serial conferences listed below are open to
all health care providers of Aurora Health Care,
Please note new time and room locations of
conferences in 2001.

TUMOR BOARD
]

Weekly luncheon Tumor Boards are held
each Friday from 12:00 noon to 1:00 pm

• St. Luke’s IViedical Center HS3
and/or the Stiemke Auditorium
• Sinai Samaritan Medical Center
Rapkin Auditorium

GI CONFERENCE
Weekly breakfast meetings are held each
Thursday from 7:00 am to 8:00 am
• St. Luke’s Medical Center HS3
Each of the above conferences offer Continuing Medical
Education (CME) credit.
The format suggested for the above serial conferences
include a prospective case presentation which consists
of a narrative medical overview, surgical findings,
projection of radiology films and pathological specimens,
and consultative discussion from the multidisciplinary
team including medical and radiation oncologists. All
types of cancers and disease site’s are presented over the
course of the year. \/ideoconferencing to broadcast an
outside speaker is available. Please call 414-649-7290
if you would like to present a case.

• West Allis Memorial Hospital
Conference Room A/B
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Business & Market

Our community outreach efforts focus on educating people in
Eastern Wisconsin about the facts that increase the risk of developing

Development

cancer, identifying ways to reduce their risk, and emphasizing the
importance of early detection. One method of reaching that goal

Cancer Services

is via our Vince Lombardi Cancer Hotline. The hotline is a toll free
service

to respond to phone inquiries about cancer from consumers,

patients, physicians and other health professionals. Hotline staff

Metro Region

put callers in touch with accurate answers to a variety of cancer
questions. Written information is often mailed to the caller or

Marija Weid man

they are referred to one of the Vince Lombardi Resource Libraries
located in our eight \7ince Lombardi Cancer Clinics. The libraries
offer computer access along with an extensive array of the latest
videos, books and pamphlets that can be checked out.
Another method of outreach is that we continue to let our
communities indicate the outreach activities that best meet
their needs. These activities have included our cancer experts
presenting information at local churches and businesses as well
as partnering on “getting the message out” at larger events with
local/regional and/or national patient advocacy groups. The
American Cancer Society Relay for Life in Washington County,
and the Susan C. Komen Breast Cancer foundation-Race for the
Cure in Milwaukee County were

two

large events that rallied our

patients and staff around a very significant message

—

that of life!

Cancer Services also hosted Aurora’s first Annual i’s’Ien’s Health
Event on September 26, 2000 at the Italian Community Center.
The event

was

co-sponsored by the “Buddies Against Prostate

Cancer” also known as Bob Reitman, Gary Grunau and Ken
Sanders. The focal topic of the conference

was

prostate cancer

with keynote speaker and prostate cancer survivor Senator
Bob Dole. Approximately 500 people attended this event to hear
Senator Dole as well as to have the unique opportunity to interact
with physicians and other health professionals on a variety of
topics such as: Heart Care, Glaucoma, Mental Health, Sleep
Disorders and Cancer.
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Vince Lombardi Cancer

LOMBARDI

Under the medical direction of Jeffrey Knajdl, MD, and with

nursing coordination and clinical services provided by Barbara

Counseling Services

Clinkenbeard, RN, MS, NP, the Cancer Counseling Center
continues its mission to identify and treat psychosocial distress
in

cancer patients.

This is born out of the recognition that nearly

50% of cancer patients will experience a high enough level of

distress to meet the criteria for a psychiatric disorder at some point
during their diagnostic, treatment, or post-treatment phase. By
decreasing levels of distress, patients may experience a host of
benefits including a higher quality of life, better nausea and pain
control, relief from depression and anxiety, improved relationships,
and even prolongation of one’s life.
This psycho-oncology program has been carefully designed under
the working models of other programs in the nation. It is the
only program like it in the state of Wisconsin. The National
Comprehensive Cancer Network (NCCN) has published

a

set

of guidelines by which psychosocial distress in cancer patients
should be managed. The Cancer Counseling Center embraces
the approach, which includes integration of decision trees for the

delivery of psychiatric, psychological, social, and spiritual services.
The NCCN also endorses the use of a psychosocial screening tool
called a “distress thermometer.” It will ultimately be used in the
Vince Lombardi Cancer Clinics to screen tfl patients
of entry

into

exploration

at

the time

the clinic system and is designed to facilitate further

into

the

nature

of patients’

distress whether it

is

a

physical, spiritual, family emotional, or other type of problem.

Treatment modalities for patients and their
families may include: 1) counseling or

Additions for the year 2000-200 1 to the
psycho-oncology program include art therapy,

psychotherapy in an individual family or
group setting, 2) psychotropic medication

pet therapy, a breast cancer psychotherapy group,
an on-site psychologist for delivery of additional

management, 3) providing access to educational
support groups, nutritional counseling, spiritual

services, and a therapist whose role would be
to offer the complementary treatment modalities

care, and other complementary services, or 4)
providing a combination of these three types

of massage, movement therapy, expressive
therapy, and guided meditation.

of intervention, which is what often occurs.

U

1

For people whose lives
have been touched
by cancer.

A Time to Grieve
Third Thursday of each month from 1:30 p.m. to 3:00 p.m.
at Aurora Health Center in the Slinrer Community Room.

The ABMT Support Group
For people who have undergone an autologous bone marrow
transplant. Held at St. Luke’s Medical Center. Call the Vince
Lombardi Hotline for meeting dates and times.

Breast Friends

To provide education,
a sharing of experiences,
and inspiration.

-

The Breast Cancer Support Group

For women who have been diagnosed with breast cancer, their
families and friends. Meets the last Tuesday of each month from
6:00 p.m., to 8:00 p.m. at St. Luke’s Medical Center in the
Cancer Counseling Center.

Care for the Caregiver Support Group
For individuals who care for an aging or disabled individual.
Every other Thursday from 10:00 a.m. to 11:30 a.m. at West Allis
Memorial Hospital.

Every Day Counts
first Wednesday and third Tuesday of each month from 1:00 p.m. to
2:00 p.m. at Aurora Health Center in the Slinger Community Room.

Experiencing Grief
Recently Widowed
For people who have lost a loved one and are going through the
grieving process. Meets Tuesdays for eight weeks from 1:00 p.m.
to 3:00 p.m. or 7:00 p.m. to 9:00 p.m. at St. Luke’s Medical Center.
To register call 414-328-6280.

Kids’ Connection
To help children ages 5 through 18 cope when a parent or loved one
has cancer. This group is offered periodically and meets for 4 weekly
sessions from 6:00 p.m. to 7:30 p.m. at St Luke’s Medical Center
in the Immunotherapy Conference Room. Registration by custodial
parent or guardian is required.

Living Through Loss Support Group
Designed to help people move through the grieving process. First
and third Tuesday of each month from 10:00 a.m. to 11:30 a.m.
or 6:00 p.m. to 7:00 p.m. at West Allis Memorial Hospital.

Look Good... Feel Better
For people who are undergoing cancer treatment.
This program presents techniques to help people
gain control and even triumph over the cosmetic
side effects of treatment. Offered six Mondays per
year from 1:00 p.m. to 4:00 p.m. Call the hotline
for dates and pre-registration.

combine education on health-related topics, along
with group sharing of feelings and experiences
related to breast cancer. MI information is strictly
confidential. Meets Wednesdays from 4:40 p.m.
6:30 p.m. at Sinai Samaritan Medical Center’s
Behavioral Health Clinic.
—

Refocusing On Hope A Support Group
For People With A Primary Brain Tumor
-

Make Today Count
For people with cancer or other life-threatening
illnesses and their families. This group is a
cooperative effort of St. Luke’s Medical Center
and the American Cancer Society. Meets the
fourth Thursday of each month Januar through
October and the third Thursday of November and
December (to accommodate the holidays) from
7:00 p.m. to 8:30 p.m. at St. Luke’s South Shore,
5900 South Lake Drive, Cudahy.

Ovarian Cancer Awareness Group
For women who are at risk for or have been
diagnosed with ovarian cancer. first Tuesday
of each month from 6:30 p.m. to 8:00 p.m. at
St. Luke’s Medical Center.

Positive People
i\lutual support, socializing, advocacy, and education
for persons with cancer, their families and friends
is provided. It also offers an opportunity to share
problems and concerns encountered while coping
with this disease. For more information call
(414) 328-7405.

Rebound

—

Living with Breast Cancer

Rebound is a highly personalized and intimate
support group for women who have recently been
diagnosed with breast cancer. The rebound program
works with breast cancer patients to address the
physical and emotional adjustments they face during
breast cancer treatment. Rebound meetings

For people who have been diagnosed with primary
brain tumors, their families and, friends. For
information on the meeting location, dates,
and time, please call the Vince Lombardi
Cancer Hotline.

Us Too! The Prostate Cancer
Support Group
-

For men who have experienced prostate cancer
and their families and friends. Meets the first
Wednesday of each month from 7:00 p.m. to
8:30 p.m. at St. Luke’s New Berlin Health Care
Center, 14555 West National Avenue, New
Berlin, in the Community Events Room.

Women Supporting Women
Breast Cancer Survivor Group
For women of color who have experienced breast
cancer. Women of color who are supportive of
each other. Meets the third Saturday of every
month from 11:00 a.m. to 1:00 p.m. at House
of Peace, 17th and Walnut.

Your Caring Connection
For patients experiencing cancer, their families
and friends. Meets the second Monday of each
month from 6:30 p.m. to 8:00 p.m. at St. Luke’s
Medical Center in the Cancer Counseling Center.
For more information, please call the Vince
Lombardi Cancer Hotline.

For more information, please call the Vince Lombardi
Cancer Hotline at 1-800-252-2990 or 414-649-7200.
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TABLE

SITE

1999 Primary Site Table For Metro Region Cancer Programs
HMH

SSMC

SLMC

WAMH
A

N/A

A

N/A

A

N/A

A

N/A

3001

468

45

1753

290

309

33

80

23

Oral Cavity
Lip
Tongue
Gum
Floor of Mouth
Palate
Other Parts Mouth
Parotid Gland
Tonsil
Oropharynx
Nasopharynx
Pyriform Sinus
Hypopharynx
Other

5
16
2
4
1
4
8
7
6
4
2
3
5

1
1
0
0
0
0
0
0
0
0
0
0
4

0
1
0
0
0
0
0
0
0
0
0
0
1

4
11
1
3
1
3
6
6
2
3
2
1
0

0
2
0
0
0
1
2
1
1
0
0
0
0

0
1
1
0
0
0
0
0
3
1
0
2
0

0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
1
0
0
0
0
0
0
0
0
0

Digestive System
Esophagus
Stomach
Colon
Rectum
Anus/Anal Canal
Liver
Pancreas
Other

44
37
232
65
6
27
77
26

6
4
39
12
1
1
7
8

0
0
4
1
0
0
0
0

26
28
129
33
4
19
51
16

3
2
16
6
1
0
6
0

7
1
25
11
0
3
12
2

0
1
2
0
0
2
0
0

2
1
15
1
0
0
1
0

0
0
2
1

Respiratory System
Nasal/Sinus
Larynx
Lung/Bronchus
Other

6
25
430
13

0
0
67
0

0
0
8
0

4
20
277
10

1
2
33
0

1
2
36
2

0
1
2
0

0
0
7
1

0
0
0
0

Blood & Bone Marrow
Leukemia
Other

106
4

13
0

3
0

64
0

14
0

6
3

0
1

3
0

3
0

12

1

0

8

3

0

0

0

0

27

1

0

21

2

2

1

0

0

54
114

6
12

1
0

34
55

8
40

2
7

1
0

0
0

2
0

All Sites

Bone
Connect/Soft Tissue

Skin
Melanoma
Other

Paae

6

2
0
0

7999 Primary Site Table For Metro Region Cancer Programs
WAMH

SLMC

SSMC

HMH

A

N/A

A

N/A

A

N/A

A

N/A

3001

468

45

1753

290

309

33

80

23

543

102

6

266

41

96

7

22

3

Female Genital
Cervix Uteri
Corpus Uteri
Ovary
Vulva
Other

90
90
58
16
7

18
15
9
2
0

0
1
0
0
0

35
55
32
10
4

4
4
11
1
1

25
7
2
3
2

2
2
2
0
0

6
6
1
0
0

0
0
1
0
0

Male Genital
Prostate
Testis
Other

340
17
2

57
0
1

11
0
0

223
13
1

30
1
0

11
2
0

2
0
0

3
1
0

3
0
0

Urinary System
Bladder
Kidney/Renal
Other

134
84
3

26
14
1

6
0
0

71
56
1

16
9
1

7
3
0

2
0
0

5
2
0

1
0
0

Brain & CNS
Brain
Other

45
4

3
0

0
0

39
3

3
1

0
0

0
0

0
0

0
0

Endocrine
Thyroid
Other

33
1

7
0

0
0

21
1

1
0

2
0

2
0

0
0

0
0

99

17

2

47

18

8

2

1

4

61

11

0

32

4

11

1

2

1

0

1

0

0

0

0

0

3001

468

45

1753

290

309

33

80

23

All Sites
Breast

Lymphatic System

Unknown Primary
0

Other/Ill-Defined
Totals

This report INCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial
A=Analytical, NA=Non-Analytical
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INCIDENCE OF NEW CANCER CASES
1995—1999
3,001 new cancer cases were seen in the Metro Region in 1999. The number of new cancer cases has increased at all the

facihties from the previous year of 1998. Site numbers include St. Luke’s Medical Center 2,043 (includes St. Luke’s South
Shore) with 86% classified as analytic (diagnosed and or treated within the first course of treatment), Sinai Samaritan Medical
Center, 342 with 90% analytic, West Allis Memorial 513 with 91% analytic and hartford Memorial with 78% analytic.

Incidence of New Cancer Cases
2500

• SLMC

• 8SMC

I

WAMH

I
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2043
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NEW CASES BREAKDOWN
Anah’tical vs. NonAnah’tical (First Course vs. Subsequent Rx)
The analytical percentages at each facility are as follows: St. Luke’s Medical Center 86% classified as analytic
(diagnosed and or treated within the first course of treatment), Sinai Samaritan 1\’Iedical Center, 90% analytic,
West Allis Memorial 91% analytic and Hartford Memorial with 78% analytic.

New Cases Breakdown-Analytic vs. Non-Analytic
(First Course vs. Subsequent Rx)
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Metro Region’s Top Ten Sites
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Total

SLMC

WAMH

SSMC

HMH
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Prostate
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Colorectal
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BENCHMARK COMPARISONS TOP 5 SITES
When comparing the top five sites in order of decreasing frequency in the Metro region to the incidence of cancer cases
reported b the state and the National Cancer Data Base (NCDB), it is noted that the Metro region sees a higher percentage
of breast cancer cases (19%), fewer prostate cases (9%) and a relatively equal number of lung (14%), colorectal (12%), and
bladder cases (5%).
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RACE BY HOSPITAL
Review of all (3,001) new cases in 1999 shows the population served at St. Luke’s Medical Center, West Allis Memorial
Hospital and Hartford I\’lemorial Hospital is predominantly white with 97%, 99% and 100% respectively. By contrast the
central city location of Sinai Samaritan Medical Center serves a more diverse population with the majority being of African
American (53%) descent.
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MALE VS. FEMALES
More women than men were seen at all Metro region sites in 1999. In total, 1,638 or 55% were women with 1,363 or 45%
being male. According to the State of Wisconsin’s Cancer Incidence and i’vlortality Report for 1998, cancer rates were higher
for men than women for all primary sites groups. The annual cancer incidence rate was 432 per 100,000 population for males
and 339 per 100.000 population for females. Of the total number of cases the incidence was split 50/50.
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AGE AT DIAGNOSIS WITHIN METRO
When comparing age differences among the Metro Region Hospitals we find younger patients being diagnosed at Sinai
Samaritan Medical Center with a mean age of 65. At St. Luke’s Medical Center and West Allis Memorial the mean age is 75
with St. Luke’s Medical Center showing a larger portion of the patients being diagnosed younger than the mean, whereas at
West Allis Memorial Hospital, the patients are being diagnosed at ages slightly higher than the mean. Of the key findings of
the Wisconsin Cancer Incidence and Mortality report is that 60% of the newly diagnosed cases in 1998 were age 65 and older.
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